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ABSTRACT 
 
 
Medullary Thyroid Carcinoma (MTC) is a rare C cell-derived thyroid tumor 
secreting calcitonin. MTC is sporadic in about 75% of cases and it is a 
component of the autosomal dominant “multiple endocrine neoplasia type 2” 
(MEN2) syndrome in about 25% of the cases. MTC represents a challenging 
clinical problem, as most MTC patients show distant metastases at time of 
diagnosis and chemotherapy and radiotherapy have limited efficacy. MTC is 
commonly associated to germline or somatic point mutations causing a gain-of-
function of RET receptor tyrosine kinase. Given the oncogenic role of RET, it 
is feasible that specific targeting of this kinase could block tumor growth. 
Therefore, tyrosine kinase small molecule inhibitors (TKI) have been studied 
as potential novel agents for MTC treatment. The clinically most advanced 
RET TKIs are vandetanib (ZD6474) and cabozantinib (XL184), both recently 
registered for the treatment of locally advanced or metastatic MTC. However, 
cancer patients may be refractory to TKIs or develop secondary resistance after 
an initial response. Two major mechanisms have been envisaged to allow 
cancer cells to escape treatment with TKIs: 1) target up-regulation or mutations 
impairing drug binding; 2) activation of alternative pathways that bypass drug-
mediated block. Thus, it is worth studying in preclinical models, molecular 
mechanisms of resistance to TKIs, since these informations can be thereafter 
clinically applied. In this dissertation, we have addressed molecular 
mechanisms of resistance to RET TKIs in cultured MTC cells. Our results 
show that MTC cells can develop resistance to chronic vandetanib treatment. 
Vandetanib-resistant cells show increased proliferation rate, anchorage-
independent growth and in vivo tumorigenicity. Despite the absence of 
secondary RET genetic lesions, resistant cells escape RET inhibition and, 
differently from parental cells, they are able to grow even when RET is 
inhibited. Importantly, resistant cells feature hyper-activation of p90RSK 
kinase, a component of the MAPK (mitogen activated protein kinase) signaling 
cascade, a fact that mediates RET inhibition bypass. Accordingly, resistant 
cells are sensitive to p90RSK chemical blockade. In conclusion, gain of MAPK 
cascade signaling seems to be able to mediate escape from RET inibition in 
vitro, thus suggesting p90RSK as a promising molecular target to overcome 
resistance formation to RET TKIs.  
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1.0 BACKGROUND   
1.1 Thyroid gland 
 
The thyroid gland secretes thyroid hormones that control metabolism 
(Kondo et al. 2006). This gland is formed by two lobes connected by an 
isthmus (Santisteban 2012). Thyroid parenchima is composed of two types of 
cells: follicular cells, that are the most abundant and are responsible for iodine 
uptake and L-thyroxine (T4) and L-triiodothyronine (T3) hormones production, 
and parafollicular C cells that secrete the calcium-regulating hormone 
calcitonin (Kondo et al. 2006). Most of the thyroid follicular cells are derived 
from the endoderm. Instead, the C cells are of neural crest derivation and 
migrate from the ultimobranchial body to finally distribute in small clusters 
among the follicles in the intermediate part of the thyroid lobes (DeLellis et al. 
2004; Santisteban 2012). Thyroid hormones production is controlled by the 
hypothalamic–pituitary axis, while calcitonin secretion is stimulated by 
elevated plasma calcium concentration (Kondo et al. 2006). 
   
1.2 Thyroid carcinoma  
Thyroid cancer is the most prevalent endocrine malignancy accounting 
for approximately 1% of cancers (DeLellis et al. 2004; Xing 2013; De Biase et 
al. 2014). Carcinomas derived from thyroid follicular cells are subdivided in 
well-differentiated thyroid carcinoma (WDTC), comprising follicular thyroid 
carcinoma (FTC) and papillary thyroid carcinoma (PTC), poorly differentiated 
thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC). It is 
possible that in some cases, PDTC and ATC develop as a result of 
dedifferentiation of a pre-existing WDTC. However, the different types of 
thyroid cancer can also form starting from different types of thyroid stem or 
progenitor cells (Todaro et al. 2010). Thyroid cancers greatly differ in terms of 
biological, pathological and clinical aggressiveness. The 25-year cause-specific 
survival is 95% for patients with PTC and 66% for patients with FTC; the 10-
year survival in patients with PDTC is approximately 40%, and ATC is 
virtually incurable (Wells et al. 2014). 
Medullary thyroid carcinoma (MTC) accounts for about 5% of thyroid 
cancers. MTC occurs sporadically in about 3/4 of the cases, but in 25% of 
cases it is hereditary in the frame of multiple endocrine neoplasia (MEN) type 
2A or 2B syndromes (Wells et al. 2013).  
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1.2.1 Follicular-cell derived thyroid carcinoma  
 
PTC is the most common thyroid carcinoma, accounting for about 80% 
of cases (DeLellis et al. 2004). PTC is etiologically associated to radiation 
exposure as it is demonstrated by the strong PTC incidence increase in children 
after the Chernobyl accident of 1986 (Williams 2002; Kondo et al, 2006; 
Nikiforov et al. 2011; Xing 2013). The recently published systematic genetic 
analysis of PTCs by the Cancer Genome Atlas consortium has allowed to 
comprehensively describe PTC molecular features (Cancer Genome Atlas 
Research Network. 2014). Table 1 summarizes the most common genetic 
lesions that have been so far associated to formation of PTC and other thyroid 
cancer types.  
 
 
 
 
Table 1: Summary of most common genetic lesions associated to thyroid 
carcinoma 
Genetic 
alteration 
PTC FTC PDTC ATC Sporadic 
MTC 
Familial 
MTC 
RET/PTC 
rearrangement 
∼10%  uncommon    
RET mutation     50% 
 
95% 
BRAF 
mutation 
∼60%  10-20% 10-35%   
RAS mutation ∼15%  30-45% 20-40% 20-30% 10-40%  
PI3K/AKT 
pathway  
∼5% 5-15% 5-10% 15-25%   
PPARγ  
rearrangement 
 30%     
TP53   ∼25% ∼70%   
 
 
 
 
BRAF mutations (∼60% of cases) are the most common genetic 
alterations found in PTC (Cancer Genome Atlas Research Network. 2014). 
BRAF (B-type RAF) codes for a component of the RAF family of serine-
threonine kinases, involved in the RAS/ERK signaling cascade (Chong et al. 
2003). Upon binding to RAS-GTP, RAF proteins dimerize and undergo 
phosphorylation in their regulatory region; this is followed by RAF-mediated 
phosphorylation of the MEK dual kinases (MEK1 and MEK2), which, in turn, 
dually (tyrosine and threonine) phosphorylate and activate p44 and p42 ERKs. 
In cancers such as melanoma and PTC, BRAF is oncogenically activated by 
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point mutations within its kinase domain; the most frequent (approximately 
90%) BRAF mutation is represented by the substitution of a glutamic acid for a 
valine at position 600 (V600E) (Xing 2013). Mutations in HRAS, KRAS, or 
most commonly NRAS occur in ∼15% of PTCs and are associated to follicular 
variant PTC (FV-PTC) (Garcia-Rostan et al. 2003; Nikiforov et al. 2011; 
Cancer Genome Atlas Research Network. 2014). The most common (∼7%) 
PTC-associated chromosomal rearrangements are paracentric inversions, or 
less commonly balanced translocations, targeting the long arm of chromosome 
10 and causing the formation of RET/PTC chimeric oncogenes. In these cases, 
the 3'-terminal portion of RET receptor tyrosine kinase (RTK), coding for its 
tyrosine kinase (TK) domain (see below for a RET description), is fused with 
the 5'-terminal sequence of unrelated genes, leading to constitutive activation 
of RET catalytic function (Cancer Genome Atlas Research Network. 2014). 
Several RET/PTCs rearrangements have been reported, the most common 
being RET/PTC1 (CCDC6-RET) and RET/PTC3 (NCOA4-RET) (Santoro et 
al. 2006, 2013). In PTCs, also other RTKs, such as NTRK1, can be targeted by 
chromosomal rearrangements leading to their oncogenic activation (Greco et 
al. 2010; Cancer Genome Atlas Research Network. 2014). NTRK1 
rearrangements involve principally three fusion partners (TPR, TPM3 and 
TFG) (Greco et al. 2010). Other RTKs, such as ALK, NTRK3, MET, FGFR2 
and LTK, have also been found to be rarely rearranged in PTC (Cancer 
Genome Atlas Research Network. 2014). Finally, in those PTC cases that 
lacked any known genetic lesions, mutations in EIF1AX (Eukaryotic 
Translation Initiation Factor 1A,X-linked) have been recently identified 
(Cancer Genome Atlas Research Network. 2014). Moreover, newly identified 
mutations in PPM1D, CHEK2 as other components of the DNA-damage 
response (DDR) pathway, can occur in PTC concomitantly with MAPK driver 
(RTKs, RAS, BRAF) mutations (Cancer Genome Atlas Research Network. 
2014).  
FTC is the second most common thyroid malignancy and accounts for 
less than 10 % of thyroid cancers (De Lellis et al. 2004). Prognosis of FTC is 
worse than PTC especially in patients with distant metastases. FTC can be 
hardly differentiated from FTA (Follicular Thyroid Adenoma) and possibly 
some FTC may have evolved from pre-existing FTA (Nikiforov et al. 2011). 
FTC develops through two different pathways, involving either RAS point 
mutations or PPARγ  (Peroxisome Proliferator-Activated Receptor gamma, 
PPARγ) rearrangements. Approximately 50% of FTCs feature mutations in 
RAS. PPARγ  is a member of the nuclear-hormone-receptor superfamily and 
functions through heterodimers with the retinoid X receptor (RXR). RAS-
negative FTCs often (30%) harbour the t(2:3)(q12-13;p24-25) chromosomal 
translocation, which causes the PAX8-PPARγ  fusion by joining the region 
encoding the DNA binding domain of the thyroid transcription factor PAX8 to 
the encoding domain A-F of PPARγ ; this rearrangement can also be found in 
FV-PTC (Kroll et al. 2000; Castro et al. 2006). The PAX8-PPARγ  chimeric 
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protein has a dominant negative activity on wild-type PPARγ  and it has 
oncogenic properties in transgenic mice (Dobson et al. 2011) (Table 1). 
PDTC accounts for up to 10% of all thyroid cancers (Volante et al. 
2010). PDTC is dominated by RAS (predominantly NRAS codon 61) 
mutations (Ricarte-Filho et al. 2009; Volante et al. 2010). BRAF V600E 
mutation has also been found in approximately 10-20% of PDTCs. 
Furthermore a significant fraction of PDTC cases shows point mutations of 
TP53 (Kondo et al. 2006). PDTC features in some cases mutations or gene 
copy number alterations in PI3K (phosphoinositide-3 (OH) kinase) (PIK3CA 
gene) and its downstream effector AKT (Xing 2013) (Table 1). 
ATC accounts for about 2% of all thyroid cancers. More than 25% of 
ATC patients have coincidentally detected WDTC (PTC or FTC) from which 
ATC possibly derives (DeLellis et al. 2004; Kondo et al. 2006; Smallridge and 
Copland 2010). ATC is associated with BRAF (10-35%) or RAS (20-30%) 
mutations. BRAF mutations are mainly found in samples containing a PTC 
component (Xing 2013). Additional mutations identified in ATC include those 
targeting the CTNNB1 gene encoding beta-catenin (Garcia-Rostan et al. 2001). 
TP53 loss-of-function mutations are common (67-88%) in ATC and likely 
critical for the establishment of such an aggressive cancer phenotype. 
Components of PI3K signaling cascade are also involved in ATC (15-25%) 
(Garcia-Rostan et al. 2005; Xing 2013) (Table 1).  
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1.2.2 Parafollicular-cell derived thyroid carcinoma  
 
MTC accounts for about 5% of all thyroid cancers (Schlumberger et al. 
2008; Wells et al. 2013). MTC is sporadic in about 75% of cases and in the 
others it occurs as a component of the Multiple Endocrine Neoplasia type 2 
(MEN2) syndrome. MEN2 is divided into two major variants: MEN2A (about 
85% of cases) and MEN2B (15%), both inherited in an autosomal dominant 
fashion (de Groot et al. 2006; Wells et al. 2013; Mulligan 2014).  
MEN2A is the most common MEN2 disease subtype and characterized 
by MTC associated with pheochromocytoma in about 50% of cases, 
parathyroid hyperplasia and, rarely, cutaneous lichen amyloidosis (CLA) and 
congenital megacolon (Hirschsprung’s disease). MEN2B is the most severe 
phenotype featuring an earlier age of MTC onset associated with 
pheochromocytoma (about 50% of cases) and more rarely mucosal neuromas, 
intestinal ganglioneuromatosis, ocular (corneal nerve) and skeletal 
abnormalities (the so called marfanoid habitus) (Wells et al. 2013). A third 
MEN2 variant, initially recognized as FMTC and characterized by MTC as the 
only phenotype is currently regarded as a MEN2A subtype with reduced 
aggressiveness (Mulligan 2014).  
MEN2-associated MTC is typically bilateral and multicentric and it is 
usually preceded by multifocal C-cell hyperplasia (CCH) (Wells et al. 2013). 
Based on our current knowledge, MTC genetics is relatively simple. 
Genes commonly mutated in other types of cancer are not commonly mutated 
in MTC. Point mutations (single aminoacid substitutions or rarely small 
insertions/deletions -indels) in the RET proto-oncogene are present in about 
half of sporadic cases and virtually all familial cases. Thus, blood screening for 
RET mutations can be used to identify patients with familial form of MTC 
(Elisei et al. 2008; Romei et al. 2011) (Table 1) (see also below). RET 
mutations correlate with a more aggressive MTC phenotype in sporadic cases 
(Elisei et al. 2008; Romei et al. 2011). In some cases, RET gene amplification 
concurrent with RET mutation has been reported (Ciampi et al. 2012). 
Recently, a novel oncogenic RET fusion (MHY13/RET) has been found in one 
sporadic MTC sample negative for RET point mutations (Grubbs at al. 2015). 
Somatic mutations in HRAS, KRAS, and rarely NRAS, occur in 10–40% of 
sporadic MTCs and are almost always mutually exclusive with RET mutations 
(Ciampi et al. 2013; Moura et al. 2011). Thus, all together RET and RAS 
mutations account for about 80% driver mutations associated to MTC. A recent 
next generation sequencing screening did not reveal additional significantly 
mutated genes in MTCs (Agrawal et al. 2013). MTC can be however also 
associated to chromosome copy number alterations, including in particular 
deletions targeting the short arm of chromosome 1 (Mathew et al. 1987). 
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1.3 RET receptor tyrosine kinase 
 
The RET (REarranged during Transfection) proto-oncogene was initially 
isolated secondary to activation occurred in vitro by a DNA rearrangement in 
NIH3T3 murine fibroblasts transfected with human lymphoma DNA 
(Takahashi et al. 1985). RET is normally expressed in the developing central, 
peripheral and enteric nervous systems (Pachnis et al. 1993). Gene targeting 
experiments in the mouse demonstrated that RET is essential for renal 
organogenesis and for spermatogenesis (Schuchardt et al. 1994; Meng et al. 
2000). In adult tissues, high levels of RET are observed in brain, thymus, 
peripheral enteric, sympathetic and sensory neurons and testis. RET is 
normally expressed in C-cells, but not in follicular thyroid cells (De Groot et 
al. 2006). 
RET protein is a single-pass transmembrane polypeptide featuring three 
major domains (Fig. 1): 
1. An extracellular portion that contains four Ca2+-dependent cadherin-like 
domains and a juxtamembrane cysteine-rich region (encoded by exons 10 
and 11 of the RET gene).  
2. A hydrophobic transmembrane peptide; 
3. An intracellular region that comprises two kinase subdomains (TK1 and 
TK2) that are joined by a hinge region of 27 aminoacids. 
 RET is subject to alternative splicing of the 3' region generating three 
protein isoforms that contain 9 (RET9), 43 (RET43) and 51 (RET51) amino 
acids at their carboxyl-terminal tail downstream from glycine 1063 (Fig. 1). 
RET9 and RET51, consisting of 1072 and 1114 amino acids, respectively, are 
the main isoforms (de Groot et al 2006). These isoforms might have distinct 
signaling properties that could also result from their segregation in distinct cell 
membrane subdomains.  
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Figure 1. The RET receptor tyrosine kinase structure. The RET protein is composed of 
three regions: an extracellular domain that contains a cysteine rich region and a series of 4 
cadherin-homology domains, a transmembrane domain and an intracellular tyrosine kinase 
domain splitted in 2 subdomains. Secondary to alternative splicing at the 3'-ter, RET gene 
codes for three different proteins differring at their C-tail of 1072 (RET9), 1106 (RET43) or 
1114 (RET51) residues.   
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RET partecipates to a protein complex that binds membrane bound co-
receptors and soluble ligands. Ligands are represented by the GDNF family of 
proteins (GFLs), including glial derived neurotrophic factor (GDNF), neurturin 
(NRTN), artemin (ARTN), and persephin (PSPN). Co-receptors are 
represented by the glycosylphosphatidylinositol (GPI)-anchored GDNF-family 
receptors (GFRα) (Fig. 2). Each one of the four GFLs binds to one GFRα to 
form a GFRα/GFL complex: GDNF binds to GFRα-1 as preferential receptor, 
NRTN to GFRα-2, ARTN to GFRα-3, and PSPN to GFRα-4, although there is 
some cross-specificity (Mulligan 2014). GFRαs also occur in a soluble form 
following enzymatic cleavage of their GPI anchor.  
 
 
 
 
 
 
Figure 2. The RET protein complex. RET partecipates in a protein complex together with 
GDNF family receptors-α (GFRα) and GDNF family ligands (GFL). 
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RET activation can occur either in cis or in trans. In the cis model, RET 
and GFRαs are expressed on the same cell; the ligand binds to the membrane 
bound coreceptor and subsequently the complex brings together two RET 
molecules resulting in dimerization, TK activation and auto-phosphorylation of 
tyrosines required for intracellular signaling (De Groot et al. 2006). Membrane-
bound GFRαs are distributed within lipid rafts, detergent-insoluble cholesterol-
rich domains within the lipid bilayer of the cell membrane, which are enriched 
with signaling proteins. In its inactive form, RET is located outside the lipid 
rafts and upon cis-activation, RET is recruited to the lipid rafts by the complex 
(De Groot et al. 2006). In the trans model of RET activation, the ligand binds 
to a soluble (non membrane bound) form of the coreceptor (sGFRα). The 
complex, in turn, triggers RET activation via dimerization.  
RET plays a central role in several intracellular signaling cascades that 
regulate multiple cellular processes including survival, differentiation, 
proliferation, and migration. Specific RET tyrosine residues are phosphorylated 
upon RET activation, which serve as docking sites for various adaptor proteins 
containing SRC-homology 2 (SH2) and phosphotyrosine binding (PTB) 
domain. These phosphorylation sites include tyrosine 687 (Y687) in the 
juxtamembrane domain, Y900, Y905 in the activation loop of the RET TK 
domain, Y981 in the TK domain and Y1015, Y1062, and Y1096 in the C-
terminal tail (Fig. 3). Y1096 is present only in the long RET51 isoform (De 
Groot et al. 2006). Though Y905 corresponds to the autocatalytic residue in 
other kinases, whose phosphorylation is an early event and serves as a local 
switch to activate the kinase, its phosphorylation has been recently 
demonstrated to be delayed and to occur after than Y1062 in the C-tail is 
phosphorylated (Plaza-Menacho et al. 2014). Y905 is a binding site for 
Grb7/10 adaptors, Y981 is a docking site for c-Src, Y1015 for phospholipase 
Cγ and Y1096 for Grb2. Y1062 is embedded in a consensus sequence 
(NXXpY) for the binding to multiple PTB domain containing proteins and as 
such it is the binding site for diverse proteins including Shc, IRS1/2, FRS2, 
DOK1/4/5 and Enigma. Binding to Shc and FRS2 mediates recruitment of 
Grb2-SOS complexes leading to RAS pathway stimulation and of Grb2-
GAB1/2 complexes leading to stimulation of the PI3K pathway (Fig. 3) 
(Santoro et al. 2013; De Groot et al. 2006; Wells et al. 2013; Mulligan 2014).  
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Figure 3. RET signaling pathways. Signaling network with RET docking sites and targets 
(see text for details).  
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1.3.1 RET activated signaling pathways 
 
As mentioned above, RET Y1062 plays a central role in activating the 
two signaling pathways: RAS/ERK and PI3K/AKT (Fig. 4). Below, we 
summarize main features of these two signaling pathways (Mendoza et al. 
2011). 
ERKs belong to the Mitogen-activated protein kinases (MAPKs), Ser/Thr 
kinases that trigger a wide range of cellular responses (Widmann et al. 1999). 
The MAPK pathway is activated principally by cell surface receptors, such as 
receptor tyrosine kinases (RTKs) but also heterotrimeric G protein-coupled 
receptors (GPCRs) (Raman et al. 2007). Upon stimulation, ERKs (ERK1/2) 
phosphorylate a large number of cytosolic and nuclear substrates. Some of the 
ERK substrates are members of the AGC family proteins, one of the most 
evolutionary conserved group of kinases, containing 60 of the 518 human 
protein kinases (Pearce et al. 2010). AGC proteins consensus sequences for 
substrate phosphorylation display a marked preference for basic residues 
(Arginine and Lysine) N-terminal to the phosphorylatable Serine or Threonine. 
Because they have similar substrate preferences, several AGC kinases can 
phosphorylate the same proteins. ERK1/2 activate AGC kinases such as the 90-
kDa ribosomal S6 kinases (p90RSKs). p90RSKs are a family of Ser/Thr 
kinases initially discovered for their ability of phsophorylating the S6 
ribosomal protein (Erikson et al. 1985) (Fig. 4). p90RSK family includes four 
members (p90RSK1–4) and two homologues named RSK-like protein kinase 
(RLPK), also known as mitogen- and stress-activated kinase-1 (MSK1), and 
RSKB (also known as MSK2) (Anjum and Blenis. 2008).  
The PI3K/AKT signaling pathway is involved in controlling cell growth, 
proliferation, motility and survival. Class I PI3K is activated by both RTKs and 
GPCRs. Its p110 catalytic subunit (PIK3CA) contains a binding site for the p85 
regulatory subunit that mediates binding to membrane receptors. Catalytic 
PI3K subunit can also be activated directly by binding to RAS-GTP. Once 
activated, PI3K mediates phosphorylation of membrane lipid 
phosphatidylinositol-4,5-bisphosphate to produce phosphatidylinositol-3,4,5-
trisphosphate (PIP3). PIP3 binds the PH domain of the AKT (PKB) protein 
kinase to localize it to the cell membrane, where finally AKT becomes 
phosphorylated and activated by the phosphoinositide-dependent kinases 
(PDK). PDK1 phosphorylates AKT at Thr308 while phosphorylation of a 
residue in the hydrophobic motif (Ser473) is required for maximal activity and 
mediated by mammalian target of rapamycin complex 2 (mTORC2). This 
system has remarkable similarities with the previously described ERK one; 
AKT is an AGC family kinase and its downstream substrates include 
mammalian target of rapamycin (mTOR), a member of the mTORC1 complex 
(mammalian target of rapamycin complex 1), that in turn phosphorylates 
another AGC family S6 kinase, named p70S6K (p70 ribosomal S6 kinase) 
(Pearce et al. 2010). 
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Figure 4. Similarities and cross-talk between RAS/ERK and PI3K/AKT pathways. 
(Modified from Mendoza et al. 2011) 
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1.3.2 RET in medullary thyroid carcinoma 
 
MEN2A and MEN2B are caused by germline mutations in RET, leading 
to its activation in the absence of ligands. Mutations are primarily aminoacid 
substitutions affecting a small number of RET codons in either the extracellular 
domain or kinase domain; rarely they consisted in small indels (Wells et al. 
2013). 
MEN2A mutations are substitutions of one of 6 cysteine residues in the 
RET extracellular domain (exons 10 or 11) (609, 611, 618, 620, 630, 634). 
C634 is the most frequently affected (85%), mainly by a C634R substitution. 
Mutations of residues 768, 790, or 804 (exons 13 and 14) of the RET TK 
domain have also been found in patients affected by isolated familial MTC 
(Wells et al. 2013; Mulligan 2014). Another recurrent mutation associated with 
MEN2A phenotype is the G533C substitution in the extracellular domain (Fig. 
5). 
Most MEN2B patients show the substitution of a methionine with a 
threonine at residue 918 (M918T) in the RET kinase domain (exon 16) whereas 
only a small fraction of them harbor the A883F substitution (exon 15). The 
M918T mutation occurs somatically in the vast majority of RET mutant 
sporadic MTCs, where it associates with more aggressive disease and poor 
prognosis (Wells et al. 2013; Mulligan 2014). MEN2B also associates to 
double mutations: V804M/E805K (Cranston et al. 2006), V804M/Y806C 
(Miyauchi et al. 1999), and V804M/S904C (Menko et al. 2002). It appears that 
the combination of two mild intracellular mutations can cooperate to produce a 
more severe mutant (Fig. 5). 
Mechanisms leading to RET oncogenic conversion and constitutive 
kinase activation in familial or sporadic MTC depend on location of the amino 
acid change. Extracellular mutated cysteines normally form intramolecular 
disulfide bonds in the wild-type receptor; thus, cysteine ablation may render 
the partner cysteine free to form an activating intermolecular -S-S- bridge, thus 
leading to the formation of covalent RET dimers with constitutive kinase 
activity (Santoro et al. 1995). RET mutations affecting intracellular domain 
probably cause protein conformational changes that relax kinase autoinhibition, 
increase ATP binding and/or increase the ability of the kinase to transfer 
phosphate groups to substrates. M918T substitution lies in the substrate-
binding pocket of the kinase; it appears to increase RET-ATP binding affinity 
and disturb the normally autoinhibited RET TK structure thereby making RET 
more active (Plaza-Menacho et al. 2014). 
As previously mentioned, a novel oncogenic RET fusion has been 
recently found in MTC. Sequencing of RNA derived from a frozen tumor 
sample proved the existence of an in-frame fusion transcript joining MYH13 
(myosin, heavy chain 13, skeletal muscle) exon 35 with RET exon 12. 
Consistent with other oncogenic RET fusions (RET/PTC rearrangements) 
overexpression of the kinase domain by the MYH13/RET exhibited in vitro 
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transforming activity. Thus, in MTC RET can rarely be activated secondary to 
gene rearrangements (Grubbs at al. 2015).  
 
 
 
 
 
 
Figure 5. Schematic representation of most common RET point mutations associated to 
MTC. For a more complete list, see Ref. Wells et al. 2013.  
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1.3.3 RET in other types of cancer 
 
Besides MTC, RET is targeted by gain-of-function genetic lesions in 
other cancer types (Santoro et al. 2013). As described above, somatic lesions of 
RET involve a rearrangement of the RET locus, at chromosome 10q11.2, in 
about 7.0% of PTCs (Cancer Genome Atlas Research Network. 2014). These 
rearrangements collectively named “RET/PTC” are significantly more 
prevalent in young age patients and in patients with a history of accidental or 
therapeutic radiation exposure, as demostrated by their increase in pediatric 
PTCs after the Chernobyl nuclear accident (Kondo et al. 2006; Williams 2008; 
Mulligan 2014). There are several types of RET/PTC fusions, as determined by 
the type of RET partner gene involved (Fig. 6). RET/PTCs form as the 
consequence of genetic recombination between the 3′ TK portion of RET and 
the 5′ portion of a partner gene, such as the coiled-coil domain-containing gene 
6 (CCDC6; also known as H4) in RET/PTC1 and the nuclear receptor co-
activator 4 (NCOA4; also known as ELE1) in RET/PTC3 (Santoro et al. 2006; 
Mulligan 2014). Virtually all the translocated amino-termini fused to RET are 
predicted to fold into coiled coils that are able to mediate protein dimerization; 
such protein-protein interaction, in turn, mediates ligand-independent RET 
kinase activation. The genomic mechanism that underlies the rearrangements 
might be explained by the specific subnuclear architecture found in thyroid 
cells. Loci that are involved in RET/PTC rearrangements lie in close proximity 
in the interphase nucleus, this favouring their illegitimate recombination 
(Nikiforova et al. 2000). Moreover, fragile DNA secondary structures in RET 
intron 11 might favour DNA breakage and subsequent recombination in 
response to radiation-induced DNA damage (Nikiforova et al. 2000). 
Consequently, RET/PTC acts as a classical oncoprotein that is able to activate 
the MAPK and PI3K/AKT pathways (Miyagi et al. 2004).  
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Figure 6. Schematic representation of RET/PTC rearrangements in PTC 
 
 
 
Similarly to PTC, RET oncogenic conversion secondary to chromosomal 
rearrangements, has been identified in two chronic myelo-monocytic leukemia 
(CMML) and one primary myelofibrosis cases. In particular, BCR/RET and 
FGFR1OP/RET generated by two balanced translocations t(10;22)(q11;q11) 
and t(6;10)(q27;q11) respectively, were isolated from these hematopoietic 
neoplasms. Similarly to RET/PTC rearrangements, the 5' part of the leukemia-
associated fusion genes encodes dimerization domains, thus mediating RET 
TK activation. These RET fusion genes are able to transform hematopoietic 
cells and impair the hematopoietic differentiation program (Ballerini et al. 
2012; Bossi et al. 2014).  
RET gene fusions have also been found in Non-Small Cell Lung Cancer 
(NSCLC). In particular, 1-2% of patients affected by lung adenocarcinoma 
(LADC) presented a pericentric inversion on chromosome 10 joining exons 1–
15 of KIF5B (kinesin family member 5B) to exons 12–20 of RET. KIF5B 
exons 1–15 comprise the kinesin motor and coiled-coil domains that mediate 
homodimerization (Lipson et al. 2012). Different breakpoints leading to 
various KIF5B-RET fusions have been identified. The KIF5B-RET fusion 
leads to aberrant activation of RET kinase and it is considered a new driver 
mutation of LADC, because it is mutually exclusive with lesions of other 
LADC-associated oncogenes (EGFR, KRAS, HER2 and ALK) (Kohno et al. 
2012). In LADC, less commonly, the RET TK was fused to the first exon of 
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CCDC6, NCOA4 or TRIMM33 genes, as it occurs in RET/PTC1, RET/PTC3 
and RET/PTC7 respectively (Li et al. 2012; Wang et al. 2012; Drilon et al. 
2013; Kohno et al. 2013; Gainor et al. 2013) Similar RET fusions, but with 
KIF5B or alternative partner genes (GOLGA5), have been recently isolated in 
patients affected by a particular melanocyte tumor subtype (Spitz melanoma) 
that is characterized by a rare association to BRAF mutations (Wiesner et al. 
2014). 
 In the absence of structural genetic lesions, abnormal RET expression 
has been shown to occur in other tumour types. RET is expressed in 50–65% of 
pancreatic ductal adenocarcinomas, and associated to malignant transformation 
and perineural invasion (Sawai et al. 2005). RET is also up-regulated in 30–
70% of invasive breast cancers particularly in estrogen receptor-positive 
tumours. In tamoxifen-resistant breast cancer cells, RET targeting was able to 
restore tamoxifen sensitivity (Plaza-Menacho et al. 2010).  
In contrast, RET loss-of-function secondary to reduced expression or rare 
point mutations, has been found in colorectal carcinomas. Aberrant 
methylation of RET in colorectal cancer cell lines correlated with decreased 
RET expression, and the restoration of RET resulted in apoptosis of these cells 
(Luo et al. 2013).  
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1.4 Protein kinases in cancer 
 
Over 500 protein kinases have been identified to date, several of them 
affecting pathways whose dysregulation is implicated in cancer (Manning et al. 
2002; Krause et al. 2005). Point mutations, gene amplifications, chromosomal 
rearrangements or up-regulated expression target proto-oncogenic kinases 
providing them with transforming capacity. Table 2 reports a list of most 
common lesions targeting kinases in human cancer.  
 Tumor cells commonly exhibit dependence on a single (often the 
initiating) activated oncogenic pathway or protein to maintain their malignant 
proliferation and survival, a phenomenon that is called “oncogene addiction” 
(Weinstein and Joe. 2008). According to this concept, protein kinases have 
been elected as promising molecular targets for cancer therapy. There are 
several possibilities to target these proteins in cancer, including monoclonal 
antibodies that can bind to the extracellular domain of the RTK, compounds 
able to favour the proteolytic degradation of the kinase and, finally, small 
molecule protein kinase inhibitors (PKI) (Baselga 2006). In this dissertation, 
we focus in particular on small molecule RET kinase inhibitors. 
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Table 2: Kinases implicated in human cancer 
 
 Kinase Tissue/Tumor Type  Oncogenic Alteration  
EGFR Cancers of breast and lung, glioma Extracellular domain deletions & point mutations  
HER2/ErbB2 Cancers of breast, ovary, colon, lung, stomach Overexpression 
IGF-IR Cancers of colon, pancreas, breast, and ovary, MM Overexpression 
PDGFR-a Glioma, glioblastoma, HES Overexpression & translocation 
PDGFR-b CMML, glioma, DFSP Translocation  
c-Kit GIST, seminoma, mastocytosis Point mutations  
Flt3 AML  Internal tandem duplication 
FGFR1  CML, myeloproliferative disorder Translocations  
FGFR3 MM Translocation & point mutations  
FGFR4 Cancers of breast and ovary  Overexpression  
MET  Glioblastoma, colorectal hepatocellular and renal carcinoma, HNSCC metastases 
Overexpression, translocation 
,point mutations  
RON  Colorectal and hepatocellular carcinoma Overexpression  
VEGFR2 Renal cell carcinoma, breast carcinoma Overexpression 
RET  
Papillary thyroid carcinoma, MEN2A, 
MEN2B, and sporadic MTC. Lung 
adenocarcinoma, Siptz melanoma 
Translocations and point 
mutations 
AXL Lung, colon, and breast carcinoma, AML, CML Overexpression, Translocations 
RTK 
ALK 
Anaplastic large cell lymphoma, NSCLC, 
neuroblastoma, anaplastic thyroid 
carcinoma 
Translocations, point mutations, 
amplifications 
SRC Lung, colon, breast and prostate carcinoma Overexpression, C-terminal truncation 
YES Lung, colon, breast and prostate carcinoma Overexpression 
ABL CML, B-ALL Translocation  
BTK MCL, CLL, prostate cancer Point mutations Overexpression 
CTK  
JAK2  B-ALL, polycytemia and related myeloproliferative disorders Translocation, point mutation  
AKT Multiple Overexpression 
ATM Ataxia telangectasia Point mutations 
Aurora A & B Multiple Overexpression 
CDKs Multiple Overexpression 
mTOR Multiple Overexpression 
PKCi Non-small cell lung, ovarian Overexpression  
PLK Multiple Overexpression 
BRAF Melanoma, thyroid, colon carcinoma, hairy cell leukemia, craniopharingioma Point mutation  
S6K Multiple Overexpression 
S/T Kinase  
STK11/LKB1 Peutz-Jeghers syndrome, sporadic cancers Point mutations 
LK PI3K Prostate, colorectal, breast, thyroid carcinomas Overexpression, point mutations  
 
 
Table 2: Summary of kinases mutated in cancer (modified from Zhang et al. 2009).  RTK: 
receptor tyrosine kinase, CTK: cytoplasmic tyrosine kinase, S/T Kinase: serine/threonine 
kinase, LK: lipid kinase. MM: Multiple Myeloma; HES: Hypereosinophilic Syndrome; 
CMML: Chronic Myelomonocytic Leukemia; DFSP: Dermatofibrosarcoma Protuberans; 
AML: Acute Myelogenous Leukemia; GIST: Gastrointestinal Stromal tumor; HNSCC: Head 
and neck squamous cell carcinoma; MEN2: Multiple Endocrine Neoplasia; MTC: Medullary 
Thyroid Carcinoma; CML: Chronic Myelogenous Leukemia; ALL: Acute Lymphoblastic 
Leukemia; NSCLC: Non Small Cell Lung Cancer; MCL: Mantle Cell Lymphoma; CLL: 
Chronic Lymphocytic leukaemia. 
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1.5 Small molecule protein kinase inhibitors 
 
Protein kinases are defined by their ability to catalyze the transfer of the 
terminal γ-phosphate of ATP to substrates that usually contain a serine, 
threonine or tyrosine residue. Kinase domains are typically arranged into 12 
subdomains that fold into a bi-lobed (N-terminal and C-terminal) catalytic core 
with ATP binding site mapping between the 2 lobes (Manning et al. 2002). Into 
the ATP pocket there is a residue called the “gatekeeper” (for instance T315 in 
ABL, T790 in EGFR and V804 in RET), whose mutation mediates kinase 
resistance to PKIs. In addition, kinases have a conserved activation loop (A-
loop, AL), which is important in regulating opening of the ATP and substrate 
binding pockets. Conserved DFG (Asp-Phe-Gly) and APE (Ala-Pro-Glu) 
motifs are present at the start and end of the AL, respectively (Manning et al. 
2002; Liu and Gray. 2006) (Fig. 7). 
 
 
 
 
 
 
Figure 7. Top: schematic representation of the kinase domain structure and the role of 
the activation loop (AL). Bottom: kinase inhibitors are divided into 2 classes (type 1 and 
2) depending on structural constraints (AL open/closed, DFG in/out) dictating their 
binding to cognate kinase. 
   27 
PKIs (or TKIs for tyrosine kinases) are small organic compounds that 
have been designed to fit within the kinase domain and block the function of 
the kinase (Fig. 7). Covalent PKIs bind covalently to the ATP-site thus 
preventing ATP binding (Liu and Gray. 2006). Non-covalent PKIs can be 
further classified into type 1 and type 2 reversible inhibitors (Zhang et al. 
2009). Type 1 inhibitors, such as gefitinib, erlotinib, vandetanib, dasatinib and 
sunitinb, are pure competitive ATP-mimetics; they bind to the active (AL 
open) conformation of the kinase (referred to as DFG-in). Instead, the type 2 
PKIs, such as imatinib, nilotinib, ponatinib or sorafenib bind to the inactive 
(AL closed), called “DFG-out conformation” taking contacts not only with the 
ATP site but also with an additional hydrophobic pocket, referred as the 
“allosteric site”, adjacent to the ATP one (Zhang et al. 2009). 
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1.6 Kinase inhibitors in thyroid cancer: RET inhibitors 
 
Based on the common presence of oncogenic conversion in proto-
oncogenic kinases (BRAF, RET, NTRK1, AKT), thyroid cancer is felt to be an 
attractive candidate whereby to explore the efficacy of PKIs. While WDTC 
patients can take advantage of capability of their tumors to concentrate 
radioactive iodine to treat local and metastatic disease, the same does not apply 
to undifferentiated follicular-cell derived thyroid carcinomas as well as to MTC 
(Wells et al. 2014). Total thyroidectomy, with or without resection of lymph 
nodes in the neck, is the primary treatment for patients with MTC. Treatment 
of MTC at an early stage is associated with a 25-year cause-specific survival of 
80%, but 10-year survival is less than 50% in patients with distant metastases. 
Family members with hereditary MTC who are diagnosed by direct DNA 
analysis can be treated by early thyroidectomy (Wells et al. 2013). Cytotoxic 
chemotherapy and radioterapy have limited efficacy in patients with 
unresectable or metastatic MTC (Schlumberger et al. 2008; Wells et al. 2013).  
The role of RET in MTC, as well as its contribution to other cancer types 
(PTC, LADC, CMML, Spitz melanoma), makes it an important target for 
therapeutic intervention in multiple diseases (Santoro et al. 2014). To date, two 
TKIs, vandetanib and cabozantinib have been approved for the treatment of 
locally advanced and metastatic MTC. Trials of additional multi-kinase 
inhibitors in thyroid cancer are in progress (Table 3). Some of these inhibitors 
target RET and therefore might be useful in MTC. These agents are 
multitargeted and able to inhibit several kinases besides RET, most commonly 
VEGFRs (Table 3). It is feasible, that combined action on several targets 
(polypharmacology) may have the advantage of blocking simultaneously 
multiple pathways active in both tumor parenchyma and stroma (Knight et al. 
2010).  
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Table 3. Tyrosine kinase inhibitors in current trials for thyroid carcinoma. 
Drug Targeted tyrosine kinases Clinical trials 
Axitinib VEGFR1-3, PDGFR, c-Kit Phase I-II 
Cabozantinib VEGFR-2, RET, MET FDA approved 
Imatinib RET, c-KIT, PDGFR Phase  I-II 
Lenvatinib VEGFR1-3, FGFR1-4, KIT, 
PDGFRβ, RET 
Phase III 
Motesanib VEGFR1-3, PDGFR, c-Kit, 
RET 
Phase I-II 
Nintedanib FGFR1-3, PDGFR, VEGFR1-3, 
RET 
Phase II 
Pazopanib VEGFR, PDGFR, c-Kit Phase II 
Ponatinib ABL, FLT-3, KIT, FGFR, 
PDGFR, VEGFR, RET 
Phase II 
Sorafenib VEGFR1-3, PDGFR, RET, RAF, 
c-Kit 
Phase I-II 
Sunitinib PDGFR, VEGFR1-3, c-Kit, RET, 
CSF1R, FLT3 
Phase I-II 
Vandetanib  VEGFR2-3, RET, EGFR FDA approved 
 
 
Abbreviations: CSF1R, macrophage colony-stimulating factor 1 receptor; EGFR, Epidermal 
growth factor receptor; FGFR, Fibroblast growth factor receptor; FLT3, FL cytokine receptor 
3; PDGFR, Platelet-derived growth factor receptor; VEGFR, Vascular endothelial growth 
factor receptor. (Mulligan 2014; Wells et al. 2013) 
 
 
 
Vandetanib (ZD6474) is a type 1 TKI (Wedge et al. 2002; Herbst et al. 
2007). X-ray diffraction has shown that it binds to the ATP-binding pocket of 
the RET kinase (Knowles et al. 2006). The compound inhibits RET with an 
inhibitory concentration 50 (IC50) of 100-130 nM (Carlomagno et al. 2002; 
Herbst et al. 2007). Its activity was initially demonstrated in RET/PTC3, RET 
C634R and RET M918T transfected NIH3T3 cells (Carlomagno et al. 2002), in 
a transplanted mouse model of human MTC (Johanson et al. 2007) and in a 
Drosophila model of RET-mediated tumorigenesis (Vidal et al. 2005). 
Vandetanib shares with other RET TKIs (sorafenib, sunitinib, cabozantinib) the 
capability of targeting vascular endothelial growth factor receptor type 2 
(VEGFR2/KDR) (IC50 = 38-40 nM), VEGFR3 (Flt-4) (IC50 = 110-260 nM) and 
VEGFR1 (Flt-1) (150-1000 nM) (Wedge et al. 2002; Bianco et al. 2008). In 
addition, vandetanib targets also the epidermal growth factor receptor (EGFR) 
(Wedge et al. 2002; Ciardiello et al. 2003; Bianco et al. 2008). Vandetanib was 
studied in a Phase III clinical trial in MTC and found to be able to prolong 
progression free survival of MTC patients with respect to placebo. Based on 
these data, it has been approved by US Food and Drug Administration for the 
treatment of locally advanced or metastatic MTC (Wells et al. 2012; Thornton 
et al. 2012). 
Cabozantinib (XL184) is another type 1 oral tyrosine kinase inhibitor, 
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also known as a multikinase inhibitor (Viola et al. 2013). Cabozantinib is a 
potent inhibitor of MET and VEGFR2 with IC50 values of 1.3 and 0.035 nM, 
respectively and displayed strong inhibition of several other kinases that have 
also been implicated in tumorigenesis, including KIT, RET, AXL, TIE2 and 
FLT3 (Grüllich et al. 2014; Mologni et al. 2013; Bentzien et al. 2013). A phase 
III clinical study was conducted in 330 patients with locally advanced or 
metastatic MTC with documented RECIST progression. Cabozantinib 
treatment resulted in prolongation-free survival respect to placebo treated 
patients and has been registered by FDA for MTC treatment (Elisei et al. 
2013). 
Recently, we and others reported that ponatinib (AP24534), a type 2 TKI, 
inhibited purified RET kinase with the IC50 of 2 digit nM (De Falco et al. 
2013- Attached at the end of this Dissertation; Mologni et al 2013). Ponatinib 
is a BCR/ABL kinase inhibitor that was derived from a structure-guided 
strategy targeting the inactive, DFG-out conformation of ABL. It is a multi-
targeted, broad-spectrum tyrosine kinase inhibitor, which has shown inhibitory 
activities also against SRC, FLT3, FGFR, VEGFR, PDFGR and others. 
Ponatinib was FDA approved in 2012 for patients with chronic myeloid 
leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic 
leukemia (Ph+ ALL). Ponatinib was able to inhibit both wild-type and mutant 
(T315I) BCR-ABL kinases with low nM IC50 values. We could show that this 
drug was active against both of point-mutant and rearranged RET-derived 
oncoproteins, including RET/V804M, a RET mutant in the gatekeeper residue 
that displayed resistance to other tyrosine kinase inhibitors. Moreover, the drug 
was strongly active against xenografts induced in nude mice by the injection of 
TT cell (a medullary thyroid carcinoma harboring C634W RET mutation) (De 
Falco et al. 2013 - Attached at the end of this Dissertation). 
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1.7 Mechanisms of resistance to protein kinase inhibitors  
 
Despite promising results in cancer treatment with PKIs, clinical 
experience has shown that only a fraction of patients respond to targeted 
therapies, even if their tumor expresses the altered target. This kind of 
resistance is known as primary resistance. Moreover, secondary or acquired 
resistance to the treatment arises almost invariably when tumors are treated 
with PKIs (Sierra et al. 2010). Acquired resistance mechanisms can be divided 
into two main categories: 1) target-dependent and 2) target-independent 
mechanisms. 
Target-dependent resistance typically occurs through genetic 
modifications of the target. Such genetic modifications may include: point 
mutations and copy number amplifications (Sierra et al. 2010). The acquisition 
of mutations conferring drug resistance has been documented for several 
inhibitors, such as for example drugs against BCR/ABL, EGFR, FLT3, KIT 
and PDGFR (Kobayashi et al. 2005; Roumiantsev et al. 2002; Fletcher and 
Rubin. 2007; Cools et al. 2004). A prevalent mechanism is the occurrence of 
point mutations within the kinase domain, which decrease the binding of the 
PKI either directly or allosterically by making conformational changes that in 
turn impede PKI binding. The most extensive characterization of such a type of 
resistance-causing mutations has been performed for BCR/ABL in the context 
of treatment with imatinib. Typically, mutation at the gatekeeper residue 
(T315I) confers imatinib resistance to BCR/ABL. Indeed, although the 
gatekeeper residue comes in close contact with ATP binding site, it does not 
interact with ATP and therefore its mutation is able to cause resistance without 
impeding ATP binding and therefore kinase activity (Gorre et al. 2001; Liu and 
Gray. 2006). Likewise, mutation of the EGFR T790 residue to methionine 
induces resistance to gefitinib and erlotinib (Pao et al. 2005). The gatekeeper 
mutation in KIT (T670I) induces resistance to imatinib (Fletcher and Rubin. 
2007), G697R in FLT3 induces resistance to PKC412 (Cools et al. 2004) and 
the gatekeeper mutation in RET (V804M/L) induces resistance to vandetanib 
(Carlomagno et al. 2004). Evidences suggest the mutation may pre-exist in a 
minority of cancer cells, and it is then selected upon PKI treatment. This 
suggests that secondary PKIs that can bind also the mutated kinase can be used 
to overcome resistance.  
Gene amplification is another major mechanism of target-dependent 
resistance. The selective pressure of the drug can drive amplification of the 
target gene, thus leading to additional overexpression of the encoded protein 
(Sierra et al. 2010). This event has been observed in CML relapsed patients 
treated with imatinib, who displayed an increase in the BCR/ABL gene copy 
number (Gorre et al. 2001).  
Instead, target-independent mechanisms occur through activation of 
alternative pathways that allow the bypass of the drug-mediated block. In other 
words, cancer cells escape treatment by switching to an alternative-signaling 
pathway that is not inhibited by the PKI. For instance, despite blocking MAPK 
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signaling, MEK inhibitors engage feedback loops that promote hyper activation 
of the PI3K/AKT pathway through the activation of diverse RTKs. Similarly, 
feedback circuits cause mTORC1-mediated recruitment of insulin like growth 
factor I receptor kinase and resistance to PI3K inhibitors (Pettazzoni et al. 
2015). Moreover, overexpression of the MET receptor or of its ligand 
hepatocyte growth factor (HGF) accounts for EGFR acquired resistance 
(Mueller et al. 2010). A study of gefitinib-resistant cell lines and human lung 
adenocarcinoma specimens showed that HGF overexpression (coupled with 
MET activation) leads to PI3K/AKT pathway restoration in the absence of 
MET amplification (Yano et al. 2008). Signaling bypass is the typical 
mechanism of resistance to BRAF PKIs. Melanoma cells chronically treated 
with BRAF inhibitors acquire drug resistance via upregulated expression of a 
number of RTKs (Nazarian et al. 2010) or genomic amplification of COT in 
turn able to restore RAS/ERK pathway (Johannessen et al. 2010). Under these 
circumstances, co-inhibition of both pathways can be exploited to reduce tumor 
growth (Mendoza et al. 2011).  
Other mechanisms of resistance can exploit the enormous genome 
plasticity of cancer cells by modulating miRNA expression or remodeling 
chromatin. Finally, though not as commonly as with classical cytotoxic drugs 
other resistance mechanisms can cause a decrease of the effective intracellular 
concentration of the PKI (Sierra et al. 2010). Overexpression of certain ATP-
binding cassette (ABC) transporter proteins such as P-glycoprotein (MDR1/P-
gp/ABCB1) and the breast cancer resistance protein (BCRP/ABCG2) confer 
resistance to imatinib in CML or gefitinib in NSCLC (Vasconcelos et al. 2011).  
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2.0 AIM OF THE STUDY 
 
 
Preclinical and clinical studies have demonstrated that targeted therapy 
based on RET inhibition may be a promising strategy for the treatment of 
cancers in which this oncogene is involved (Santoro et al. 2014). Clinical 
experience with RET TKIs is very limited since the first drugs inhibiting RET 
have been registered less than 5 years ago (Wells et al. 2014). However, 
lessons learned from other tumor types have thought that cancer patients 
commonly develop resistance to TKIs. Resistance can be mediated by 
mutations in the target kinase that impair drug binding or other mechanisms 
that allow cancer cells bypassing signaling block exerted by the used TKI. In 
principle, the first mechanism can be overcome by second line inhibitors able 
to bind the mutated kinase, while the second one can be challenged by 
additional inhibitors able to intercept the escape pathway. Thus, it is of great 
relevance to understand molecular mechanisms of resistance to devise 
strategies to overcome it.  
In this framework, aim of this study has been to explore secondary 
resistance mechanisms to vandetanib in RET mutant human MTC cells.  
We pursued this goal by: 
1) Generating in vitro and characterizing MTC cells resistant to 
vandetanib;  
2) Analyzing the molecular mechanism involved in such resistance. 
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3.0 MATERIALS & METHODS    
3.1 Compounds   
For in vitro experiments, vandetanib was dissolved in DMSO at a 
concentration of 50 mM and stored at –80°C. BI-D1870 and PF-4708671 were 
provided by Selleckchem (Houston, TX, USA). They were dissolved in 
dimethyl sulfoxide (DMSO) at a concentration of 10 mM and stored at -80°C. 
U0126 was provided by Cell Signaling (Danvers, MA, United States); it was 
dissolved in DMSO at a concentration of 10 mM and stored at –20°C.  
 
 
 
3.2 Cell culture 
  
 TT cells were from American Type Culture Collection (ATCC) and 
authenticated by RET genotyping. TT was derived from the primary tumor of 
an apparently sporadic MTC (Berger et al. 1984). TT harbor a cysteine 634 to 
tryptophan (C634W) exon 11 RET mutation (Carlomagno et al. 1995) as well 
as a tandem duplication of the mutated RET allele (Huang et al. 2003). TT cells 
were grown in RPMI 1640 supplemented with 16% fetal calf serum (GIBCO, 
Paisley, PA) (complete medium). Media was supplemented with 2 mM L-
glutamine and 100 units/ml penicillin-streptomycin (GIBCO).  
 
 
 
3.3 Cell proliferation assay    
2x105 cells were plated in 60-mm dishes. Cells were kept in RPMI 1640 
supplemented with 16% fetal calf serum. The day after plating, compounds or 
vehicle were added. Cells were counted in triplicate every 3-4 days. To 
estimate IC50 value, cells were counted after 14 days.  
 
 
 
3.4 RNA silencing 
 
For RNA silencing, the small inhibitor duplex RNA (siRNA) (ON-target 
plus SMARTpool) siRET (#L-003170-00) from Dharmacon (Lafayette, CO, 
USA) was used. The siCONTROL Non-targeting Pool (siCTR) (#D-001810-
10-20) was used as a negative control. Cells were transfected with 100 nM 
siRNAs using Dharmafect reagent following manufacturer’s instructions. The 
day before transfection, cells were plated in 35-mm dishes at 40% of 
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confluence in RPMI 1640 supplemented with 16% FBS without antibiotics. 
Cells were harvested 48 hours after transfection.  
 
 
 
3.5 BrdU assay 
 
DNA synthesis rate was measured by 5′-bromo-3′-deoxyuridine (BrdU) 
incorporation assay performed by using 5-Bromo-2′-deoxy-uridine Labeling 
and Detection Kit I from Roche Applied Science (Penzberg, BY, Germany). 
Cells transfected with siRET and siCTR, previously seeded onto glass 
coverslips, were incubated in complete medium supplemented with 10 µM of 
BrdU for 1 h, fixed and permealized. Cells were than stained with anti-BrdU 
mouse monoclonal and with rodamine-conjugated secondary antibodies. 
Hoechst 33258 (final concentration 1 µg/mL; Sigma Chemicals Co) was used 
to counterstain cell nuclei. The fluorescent signal was visualized with an 
epifluorescent microscope (Axiovert 2, Ziess) (equipped with a 100X lens) 
interfaced with the image analyzer software KS300 (Zeiss). The percentage of 
BrdU incorporation was quantified in 10 randomly photographed fields in a 
blinded fashion.  
 
 
 
3.6 Soft agar assay 
 
Petri dishes of 60 mm diameter were prepared by adding 7 ml of 
complete medium containing 0.5% soft agar. TT cells cultured in standard 
conditions were trypsinized, centrifuged and resuspended in a single-cell 
suspension of 1x105 viable cells/ml (5x104/well). The cell suspension was 
mixed with complete medium containing 0.5% soft agar at a ratio 1:2 and then 
divided in two aliquots, one of which was supplemented with 500 nM 
vandetanib. These suspensions were seeded onto the Petri dishes containing the 
solidified agar medium (1.5 ml/dish) and incubated at 37°C and 5% CO2. 
Control and treated cultures were observed under microscope just after plating, 
to verify the absence of cell aggregates, and next periodically checked for 
colonies formation. After four weeks, colonies were counted with an optical 
microscope at a 10X magnification.  
 
 
 
3.7 Tumorigenicity in nude mice 
 
Animals were housed in barrier facilities at the Dipartimento di Medicina 
Molecolare e Biotecnologie Mediche Animal Facility. Animal studies were 
carried out according to Institutional-approved protocols in compliance with 
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the Italian Ministry of Health guide for the care and use of Laboratory 
Animals. 
TT and TT ZD/R cells (5x107/mouse) were injected subcutaneously into 
the right dorsal portion of 4-week-old female BALB/c nu/nu mice (n. 28 mice) 
from Charles River Laboratories International (Lecco, LC, Italy). Tumor size 
was assessed by caliper at regular intervals and tumor volume was calculated 
according to the formula: (LxW2)/2 (were L = length and W = width of tumor).    
3.8 Immunoblotting    Protein lysates were prepared according to standard procedures. Briefly, 
cells were harvested in lysis buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 
10% glycerol, 1% Triton X-100, 1 mM EGTA, 1.5 mM MgCl2, 10 mM NaF, 
10 mM sodium pyrophosphate, 1 mM Na3VO4, 10 µg of aprotinin/ml, 10 µg of 
leupeptin/ml) and clarified by centrifugation at 10,000 xg. Protein 
concentration was estimated with a modified Bradford assay (Bio-Rad) and 
lysates were subjected to western blot. Membranes were probed with the 
indicated antibodies. Immune complexes were revealed by an enhanced 
chemiluminescence detection kit (ECL, Amersham Pharmacia Biotech). Signal 
intensity was quantified with the Phosphorimager (Typhoon 8600, Amersham 
Pharmacia Biotech) interfaced with the ImageQuant software.  
 
 
 
3.9 Antibodies 
 
Anti-RET is a polyclonal antibody raised against the tyrosine kinase 
protein fragment of human RET (Santoro et al. 2005). Anti-phospho-Y905 and 
anti-phospho-Y1062 are phospho-specific affinity-purified polyclonal 
antibodies that recognize RET proteins phosphorylated at Y905 and Y1062, 
respectively (Carlomagno et al. 2002). Anti-phospho-SHC (#Y317), which 
recognizes SHC proteins when phosphorylated at Y317, was from Upstate 
Biotechnology Inc. Anti-phospho-PLCγ (#2821) recognizing PLCγ 
phosphorylated at Y783, anti-phospho-MAPK (#9102) specific for 
p44/42MAPK (ERK1/2) phosphorylated at Thr202/Tyr204, anti-phospho-
MEK1/2 (#9121), anti-phospho-CRAF phosphorylated at Ser338 (#9427), anti-
phospho AKT specific for phosphorylated Ser473 (#9271) or Thr308 (#9275), 
anti-phospho p90RSK specific for phosphorylated Ser380 (#9341), Thr573 
(#9346) or Thr359/Ser363 (#9344), and anti-p90RSK (#9355) antibodies were 
from Cell Signaling Technology. Antibodies recognizing BAD phosphorylated 
at Ser112 (#5284), S6 Ribosomal Protein when phosphorylated at Ser235/236 
(#2211) or when phosphorylated at Ser240/244 (#2215), YB1 phosphorylated 
at Ser102 (#2900) and p70S6 Kinase phosphorylated at Ser389 (#9234), were 
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from Cell Signaling Technology. Anti-phospho p90RSK1(S221)/ 
p90RSK2(S227) (#AF892) specific for p90RSK1 when phosphorylated at 
Ser221 and  p90RSK2 when phosphorylated at Ser227, was from R&D 
Systems. Anti phospho-p27/Kip1 (#AF3994), which recognizes p27/Kip1 when 
phosphorylated at Thr198, was from R&D Systems. Anti-p27/Kip1 (#71-9600) 
was from Invitrogen. Monoclonal anti-α-tubulin  (#T9026) was from Sigma 
Aldrich (St Louis, MO, USA).  Secondary antibodies coupled to horseradish 
peroxidase were from Amersham Pharmacia Biotech (Piscataway, NJ, USA).  
 
 
 
3.10 Statistical analysis 
  
Unpaired Student’s t tests using the Instat software program (Graphpad 
Software Inc) were performed to compare cell growth. All P values were two-
sided, and differences were considered statistically significant at P <0.01. IC50 
doses were calculated through a curve fitting analysis from last day values 
using the PRISM software program (Graphpad Software Inc). To compare 
tumour growth we used an unpaired t-student test (InStat program, GraphPad 
software). P values were statistically significant at P <0.01. 
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4.0 RESULTS 
 
 
4.1 Selection of MTC cells resistant to vandetanib 
  
 In order to generate MTC cells resistant to vandetanib, we chronically 
exposed TT cells (a human MTC cell line carrying the RET-C634W mutation) 
to the drug. We started from a dose (50 nM) that was lower than the IC50 of 
the drug for RET (100 nM) (Carlomagno et al. 2002), and stepwise scaled-up 
drug concentration (by increasing the dose of 50 nM at each step) up to 500 
nM. In this way we isolated a mass population of TT cells (named TT ZD/R) 
adapted to proliferate at this vandetanib dose. The process took about 24 
months. 
 To measure vandetanib (ZD6474)-inibitory concentration 50 (IC50) in 
TT ZD/R cells compared to parental ones, cells were exposed for 14 days to 
different doses of the inhibitor (Fig. 8). Treatment of parental cells (TT) with 
vandetanib reduced proliferation with an IC50 of about 100 nM, confirming 
previous results. Noteworthy, significantly higher doses of vandetanib were 
required to achieve 50% growth inhibition in ZD/R cells (IC50 of about 400 
nM) confirming their resistance (Fig. 8).  
 
 
 
 
 
Figure 8. TT cells chronically treated with ZD6474 develop drug resistance. Sensitivity of 
parental (TT) and corresponding resistant cells (TT ZD/R) to vandetanib (ZD6474) was 
assessed by proliferation assay. 2x105 cells were plated in RPMI 1640 supplemented with 16% 
Fetal Bovine Serum (FBS) (complete medium) in presence of different doses of ZD6474 and 
refreshed every 3-4 days. After 14 days cells were counted in triplicate: data are reported as 
percentage of cell number. Top: IC50 values with their respective 95% confidence intervals are 
reported. Sensitivity of parental and resistant cells was significantly different (p<0.001) at dose 
250 nM.  
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 We asked whether TT ZD/R resistance to vandetanib was irreversible or 
depended on continous exposure to the drug. To this aim, we cultured TT 
ZD/R cells in the absence of vandetanib (wash-out) for about 3 months. 
Vandetanib-IC50 in washed-out TT ZD/R cells (TT ZD/R wash-out) compared 
to that of TT ZD/R cells continuously kept in vandetanib was measured by a 14 
days proliferation assay with different doses of the inhibitor (Fig. 9). TT ZD/R 
wash-out cells did not change significantly vandetanib-IC50 that remained of 
about 400 nM (Fig. 9). Thus, TT ZD/R cells were irrereversibly resistant to 
vandetanib.  
 
 
 
 
 
 
Figure 9. Resistance of TT ZD/R cells was irreversible. Sensitivity to vandetanib (ZD6474) 
of TT ZD/R and washed-out TT ZD/R (TT ZD/R wash-out) cells was assessed by proliferation 
assay as described in Fig. 8. Sensitivity of the two cell lines was not significantly different 
(p>0.1) at every analyzed dose. 
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4.1.1 Cloning of resistant cells 
 
 In order to obtain pure populations of vandetanib-resistant cells, TT 
ZD/R cells were subjected to limiting dilution cloning and individual colonies 
picking. Cell cloning was carried out from mass population both in the 
presence and in the absence of vandetanib for about two months. Then, to test 
if the isolated clones were vandetanib-resistant, proliferation assays were 
performed with 500 nM vandetanib (ZD6474) for 14 days (Fig. 10A). All the 
isolated clones were resistant to the treatment. Indeed while at 500 nM 
vandetanib, parental cells growth was arrested, vandetanib-resistant clones (TT 
ZD/R CL1-11) proliferation rate was only modestly slowed down (Fig. 10A). 
To measure vandetanib-IC50, six representative vandetanib-resistant clones 
(TT ZD/R CL1, TT ZD/R CL2, TT ZD/R CL4, TT ZD/R CL9, TT ZD/R CL10 
and TT ZD/R CL11) were exposed to different doses of vandetanib for 14 days 
(Fig. 10B). All the analyzed clones, irrespectively of their previous selection in 
the presence or not of vandetanib, featured a significant vandetanib resistant 
phenotype. These data confirmed the irreversible nature of mechanism of 
resistance. 
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Figure 10. TT ZD/R cell clones are resistant to vandetanib. A) Sensitivity of parental (TT) 
and isolated TT ZD/R clones (TT ZD/R CL) to vandetanib (ZD6474) was assessed by 
proliferation assay. 2x105 cells were plated in complete medium in the presence of 500 nM 
ZD6474 and refreshed every 3-4 days. After 14 days cells were counted in triplicate: data are 
reported as percentage of cell number. On the right, are reported the approximate IC50 values 
extrapolated by a single dose curve. B) Sensitivity to ZD6474 of six representative TT ZD/R 
clones (TT ZD/R CL11, TT ZD/R CL9, TT ZD/R CL1 isolated in the absence of vandetanib; 
TT ZD/R CL2, TT ZD/R CL4, TT ZD/R CL10 isolated in the presence of vandetanib) was 
assessed by proliferation assay as described in Fig. 8. IC50 values and the relative 95% 
confidence intervals are reported.  
 
 
 
4.1.2 Resistant cells feature increased proliferation rate 
 
 Morphologically vandetanib-resistant cells were more refractile and 
spindle shaped than parental cells; moreover, they grew in clusters and were 
less adherent to the culture dish (Fig. 11).  
 
 
 
 
 
 
Figure 11. Resistant cells display an increase of the transformed phenotype. Cells (TT, TT 
ZD/R, TT ZD/R CL10, TT ZD/R CL11) were grown in complete medium. Cells were 
photographed at 50-70% of confluence with an optical microscope at 10X magnification.  
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Thus, growth curves at 15 days of resistant compared to parental cells 
were performed. At 15 days TT ZD/R cells had increased their number by 
almost 36 fold (from 109000 to 3900000 cells) whereas TT cells only by 21 
fold (from 85500 to 1830000 cells) (Fig 12).   
 To confirm these findings, we performed a 5′-bromodeoxyuridine (BrdU) 
incorporation assay able to measure DNA synthesis rate. Cells were incubated 
in complete medium for 1 h supplemented with 10 µM BrdU. Cells were fixed 
and than stained with an anti-BrdU and secondary fluorescein-conjugated 
antibodies. Hoechst was used to counterstain cell nuclei. TT ZD/R showed 
increased DNA synthesis rate (30% incorporation) compared to parental TT 
cells (20% incorporation) (Fig. 12). Error bars represent standard deviations.  
 
 
 
 
 
 
Figure 12. Resistant cells display increased growth rate. 2x105 TT and TT ZD/R cells were 
plated, in the absence of vandetanib (ZD6474), in complete medium and counted at different 
time points. Error bars represent standard deviation derived from experimental triplicates. 
BrdU incorporation assay was performed to assess TT and TT ZD/R cells DNA synthesis rate 
(inset). Cells were plated in complete medium and incubated with 10 µM 5′-
bromodeoxyuridine for 1 h. The percentage of cells in active DNA synthesis (anti-BrdU 
antibody positive) was calculated with respect to total cells (Hoechst 33258 positive). Standard 
deviations were calculated from experimental triplicates.  
   43 
4.1.3 Resistant cells display increased capability to form colonies in soft 
agar 
 
 In order to evaluate anchorage-independent growth, 5x104 TT cells, pool 
TT ZD/R and three representative resistant cell clones (TT ZD/R CL9, TT 
ZD/R CL10 and TT ZD/R CL11) were seeded in soft agar in a 60 mm dish in 
the presence or not of 500 nM vandetanib (ZD6474). Colonies were counted 
after 28 days and photographed with an optical microscope at a 10X 
magnification (Fig. 13). Resistant cells feature increased size (Fig. 13, upper) 
and number (Fig. 13, lower) of colonies with respect to parental TT cells. 
 Moreover while parental TT cells were unable to form colonies in the 
presence of vandetanib, resistant cells featured partial anchorage-independent 
growth even in the presence of vandetanib. At 500 nM vandetanib, resistant 
cells only featured a partial reduction (about 50%) in size and number of the 
colonies (Fig. 13).  
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Figure 13. Resistant cells feature increased anchorage-independent growth in soft-agar 
assay. Petri dishes of 60 mm were prepared by adding 7 ml of complete medium to 0.5% soft 
agar. 5x104 parental (TT) or resistant cells (TT ZD/R, TT ZD/R CL 9, TT ZD/R CL 10, TT 
ZD/R CL 11) were resuspended in complete medium containing 0.25% soft agar and then 
divided in two aliquots, one of which was supplemented with 500 nM vandetanib (ZD6474). 
Cell suspensions were seeded onto the Petri dishes containing the solidified agar medium. 
After four weeks the colonies larger than about 50 μm in diameter were photographed and 
counted with an optical microscope at 10X magnification. Error bars represent standard 
deviations from experimental triplicates. 
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4.1.4 Resistant cells display increased capability to form tumors in nude 
mice 
 
 An in vivo tumorigenicity assay was performed. TT and TT ZD/R cells 
(5x107/mouse) were injected subcutaneously into the right dorsal portion of 
BALB/c nude mice (20 for each group). Three weeks after injection tumor 
volumes were assessed; xenografts induced by TT ZD/R cells displayed 
increased tumor incidence than those induced by TT cells (Fig. 14). Indeed, 
after three weeks only 15% of TT injected mice and more than 90% of TT 
ZD/R injected mice showed measurable tumors (>40 mm3). Moreover the mean 
volume of tumors derived from TT cells was 32.9 mm3 whereas that of tumors 
derived from TT ZD/R cells was 327.5 mm3 (P<0.001). 
 
 
 
 
 
 
Figure 14. TT ZD/R cells feature increased in vivo tumorigenicity. TT or TT ZD/R cells 
(5x107/mouse) were injected subcutaneously into the right dorsal portion of 4-week-old female 
BALB/c nu/nu mice. After three weeks, tumor size was assessed by caliper and tumor volume 
was calculated according to the formula: (LxW2)/2 (were L = length and W = width of tumor). 
Tumors derived from TT cells measured on average 32.9 mm3 (relative standard 
deviation=73.5). Tumors derived from TT ZD/R cells measured on average 327.5 mm3 
(relative standard deviation=227.2). Statistical significance was determined by unpaired 
Student’s T test (P<0.001). 
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4.1.5 Resistant cells have no secondary genetic RET alterations  
 
Target-dependent resistance can be mediated by secondary kinase lesions 
imparing drug binding or kinase copy number gains altering drug-kinase 
stoichiometry. In the case of RET, V804 and Y806 mutations have been 
previously shown to impair vandetanib binding (Carlomagno et al. 2004; 
Carlomagno et al. 2009). Thus, we asked whether resistant cells kept the 
C634W RET mutation carried by parental cells and whether they have 
developed novel mutations possibly mediating vandetanib resistance. To this 
aim, RET cDNA was subjected to DNA sequencing in TT ZD/R pool and two 
representative resistant clones. Resistant cells kept the C634W RET mutation 
and did not feature any additional RET mutation or rearrangement (data not 
shown).  
In order to verify if resistant cells developed RET gene amplifications, 
we analyzed RET gene copy number comparing TT ZD/R to TT cells by 
quantitative PCR. It was already known that TT cells have three copy of RET 
gene (Huang et al. 2003). We found that there was no further RET 
amplification in TT ZD/R cells (data not shown).  
Finally to check if RET was over-expressed in resistant cells, we 
analyzed RET expression levels in resistant clones compared to parental cells 
by immunoblotting. In parallel, we checked RET phosphorylation at the major 
RET signaling docking site, Y1062 (Fig. 15). RET levels and RET 
phosphorylation were comparable in resistant clones with respect to parental 
cells (Fig. 15).  
All together, these results allowed to exclude that changes in RET 
contributed to vandetanib-resistance.  
 
 
 
 
 
 
Figure 15. RET expression and phosphorylation levels were not changed in resistant with 
respect to parental cells. Total cell lysates (50 µg) from parental cells (TT) and resistant 
clones were analyzed with anti-RET and anti-pY1062 antibodies by immunoblotting. Total 
tubulin levels were used for normalization. 
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4.1.6 Resistant cells are still RET-addicted  
 
In order to clarify whether the resistant cells retained RET-addicted 
proliferation as parental TT cells, we transiently silenced RET expression by 
RNA interference in parental TT cells, TT ZD/R pool and in two representative 
resistant clones (TT ZD/R CL6 and TT ZD/R CL8) (Fig. 16). The efficacy of 
small RNA interference against RET (siRET) was proved by immunoblotting; 
siRNA transfection reduced by more than 70% RET protein levels (Fig. 16). In 
resistant such as in parental cells RET silencing reduced by about 6-fold DNA 
synthesis rate measured as percentage of BrdU incorporation (Fig. 16). These 
findings indicated that resistant cells were still dependent on RET for their 
proliferation. 
 
 
 
 
 
Figure 16. Resistant cells display a RET-addicted DNA synthesis rate. RET silencing was 
performed in parental (TT) and resistant cells (TT ZD/R, TT ZD/R CL6, TT ZD/R CL8). Cells 
were plated in 35-mm dishes at 40% confluency in complete medium without antibiotics. The 
following day, cells were transfected with 100 nM small interference against RET (siRET) or 
negative control (siCTR) using Dharmafect reagent following manufacturer’s instructions. 48 
hours after transfection, cells were incubated in complete medium supplemented with 10 µM 
5′-bromodeoxyuridine for 1 h. Total cell lysates (50 µg) were analyzed with anti-RET antibody 
by immunoblotting. Total tubulin level was used for normalization. The percentage of cells in 
DNA synthesis measured by BrdU incorporation was calculated with respect to total cell 
number. Error bars represent standard deviations derived from experimental triplicates.  
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4.1.7 RET is effectively inhibited by vandetanib in resistant cells 
 
In order to verify whether vandetanib was still able to inhibit RET in 
resistant cells, RET phosphorylation was assessed upon one-hour treatment 
with different doses of vandetanib. We compared RET response to vandetanib 
(ZD6474) of TT ZD/R cells and two representative resistant clones (TT ZD/R 
CL7 and TT ZD/R CL11) with respect to parental TT cells by immunoblotting. 
RET phosphorylation was evaluated at Y1062 and Y905 sites. Consistent with 
lack of acquired secondary RET alterations, resistant cells did not show 
different RET response to vandetanib with respect to parental cells. Indeed, as 
expected for parental cells, at 100 nM vandetanib RET was approximately 50% 
inhibited in both cell types (Fig. 17).  However, about 700 nM vandetanib was 
required to blunt RET phosphorylation to less than 20% in both cell types. 
 
 
 
 
 
 
Figure 17. Vandetanib was able to inhibit RET in both parental and resistant cells. TT 
cells, TT ZD/R pool and two representative resistant clones (TT ZD/R CL7, TT ZD/R CL11) 
were treated for 1 hr with indicated concentrations of vandetanib (ZD6474). Total cell lysates 
(50 µg) were subjected to immunoblotting; RET phosphorylation was assessed with anti-
phosho Y1062 (pRET Y1062) and anti-phosho Y905 (pRET Y905) antibodies. Total RET 
level was used for normalization. 
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In order to verify the duration of RET inhibition upon vandetanib 
treatment, parental cells and two representative resistant clones (TT ZD/R CL9 
and TT ZD/R CL11) were treated with 500 nM vandetanib (ZD6474) at 
different time points and RET phosphorylation at Y1062 and at Y905 residues 
was analysed (Fig. 18). Comparable kinetics of RET inhibition and 
phosphorylation recovery were detected in resistant and parental cells, 
confirming the notion that altered RET activation levels were not directly 
involved in the mechanism of resistance (Fig. 18).  
 
 
 
 
 
 
Figure 18. Vandetanib-mediated RET inhibition was comparable in parental and 
resistant cells. Parental cells (TT) and two representative resistant clones (TT ZD/R CL9, TT 
ZD/R CL11) were treated at the indicated time points with 500 nM vandetanib (ZD6474). 
Total cell lysates (50 µg) were analyzed for RET phosphorylation with anti-phosho Y1062 
(pY1062) and anti-phosho Y905 (pY905) antibodies. Total RET level was used for 
normalization. 
 
 
 
All together, these findings indicated that functional or genetic RET 
alterations were not involved in vandetanib resistance of TT ZD/R cells, thus 
pointing to a target-independent mechanism of resistance. However, resistant 
cells remained addicted to RET, as shown by siRNA experiments, though 
threshold of sensitivity to RET inhibition was increased in resistant with 
respect to parental cells. Indeed, growth of ZD/R cells was still arrested by 
vandetanib but only when RET phosphorylation was reduced to less than 20% 
at drug doses higher than 500 nM. These findings suggested that signaling 
perturbations may have been selected in ZD/R cells to be able to compensate 
effects of RET inhibition on cell proliferation and allow cells to escape drug 
treatment effects. 
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4.2 Resistant cells show p90RSK hyper-activation 
 
To find out whether intracellular signaling was altered in resistant cells, 
initially the phosphorylation of two direct RET substrates, SHC protein, 
recruited by Y1062 phosphorylation, and PLCγ protein, recruited by Y1015 
phosphorylation was analyzed in a time-course experiment (Fig. 19A). No 
significant changes over time in these RET substrates were observed in 
resistant versus parental cells (Fig. 19A).  
Then, we studied activation of other known members of the two principal 
RET signaling pathways: PI3K/AKT and RAS/ERK signaling cascades. In 
particular, we explored PI3K/AKT pathway by studying AKT activation at the 
two main phosphorylation residues, T308, phosphorylated by PDK1, and S473, 
phosphorylated by mTORC2 (PDK2). RAS/ERK pathway was explored by 
studying CRAF, MEK and ERK (MAPK) phosphorylation (Fig. 19B). Again, 
comparable changes at each time points in phosphorylation levels of analyzed 
proteins upon vandetanib (ZD6474) treatment were noted in parental and 
resistant cells (Fig. 19B). 
 
 
 
 
 
Figure 19. Time-course of vandetanib-mediated PI3K/AKT and RAS/ERK pathways 
inhibition is comparable in parental and resistant cells. Parental cells (TT) and two 
representative resistant clones (TT ZD/R CL9, TT ZD/R CL11) were treated as in Fig. 18. A) 
Total cell lysates (50 µg) were analyzed with phospho-PLCγ (pPLCγ) and phospho-SHC 
(pSHC) antibodies. B) Total cell lysates (50 µg) were analyzed with anti-phospho AKT (pS473 
AKT and pT308 AKT), anti-phospho CRAF (pCRAF), anti-phospho MEK (pMEK) and anti-
phospho MAPK (pMAPK) antibodies.  
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To investigate more in depth the possible involvement of PI3K/AKT and 
RAS/ERK pathways in vandetanib-resistance, we checked phosphorylation 
levels of additional downstream proteins. No phosphorylation changes at each 
time points in resistant compared to parental cells were noted in the analyzed 
proteins with the exception of a hyper-activation (see below) of p90RSK, a 
serine-threonine kinase effector of RAS/ERK pathway.  
p90RSK is directly activated by MAPK and it comprises two 
functionally distinct kinase domains (NTKD: N-terminal and CTKD: C-
terminal), a linker region, and N- and C-terminal tails (Fig. 20).  
 
 
 
 
 
 
Figure 20. The p90RSK structure. p90RSK is characterized by the presence of two 
functional kinase domains, the NTKD and the CTKD, which are connected by a linker region 
of approximately 100 aa. Activation of p90RSK is associated with increased phosphorylation 
at six sites. These phosphorylation sites were shown to be either essential (221, 363, 380, 573) 
or accessory (359, 737) for p90RSK activation. The C-terminal end of the protein contains an 
ERK1/2-docking domain resembling a KIM region (kinase interaction motif), and the extreme 
C-terminus comprises a PDZ-binding motif. Activation loop (T-loop site) of each kinase 
domain is indicated. Aminoacid numbering refers to human p90RSK1 (modified from Romeo 
et al. 2012). 
 
 
 
The N-terminal p90RSK kinase domain (NTKD) belongs to the AGC family 
(Romeo et al. 2012; Frodin and Gammeltoft. 1999) and is responsible for 
phosphorylating p90RSK substrates recognizing the basophilic consensus 
motif: Arg/Lys-X-Arg-X-X-Ser/Thr or Arg-Arg-X-Ser/Thr (Frodin and 
Gammeltoft. 1999). The C-terminal kinase domain (CTKD) of p90RSK 
belongs to the CaMK (Ca2+ /calmodulin-dependent protein kinase) family 
(Romeo et al. 2012). The only known function of the CTKD is to activate the 
NTKD via autophosphorylation of the hydrophobic motif within the linker 
region and no heterologous substrate has as yet been ascribed to this kinase 
domain (Romeo et al. 2012). NTKD and CTKD are connected by a linker 
region of approximately 100 aa (amino acids) containing essential regulatory 
domains, including hydrophobic and turn motifs, involved in activation of the 
NTKD (Romeo et al. 2012). The C-terminal tail contains an ERK1/2 docking 
site, which differs from classical D-type ERK1/2 docking domains. Indeed, 
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ERK docking domain found in p90RSK appears to fit the KIM consensus 
sequence (Romeo et al. 2012). Finally, the N-terminal tail contains a potential 
nuclear localization sequence. Based on this structure, p90RSK is sequentially 
activated via coordinated phosphorylation by MAPK (ERK1/2), 
autophosphorylation, and PDK1 (Romeo et al. 2012) (Fig. 21). Briefly, upon 
mitogenic stimulation, ERK cooperatively phosphorylates p90RSK at Thr573 
(p90RSK1 numbering) located within the T loop of the C-terminal kinase 
domain and at Thr359/Ser363 in the linker region between the two kinase 
domains. Phosphorylation at Thr573 promotes activation and phosphorylation 
of Ser380 within the linker region by the C-terminal kinase domain. When 
phosphorylated, Ser380 acts as a docking site for the constitutively active 
Ser/Thr kinase PDK1, which in turn phosphorylates p90RSK at Ser221 
(p90RSK1 numbering) within the T loop of N-terminal kinase domain. Once 
PDK1 dissociates from p90RSK allowing phosphorylated Ser380 to bind a 
phosphate-binding site in the NTKD, resulting in a stable association between 
the hydrophobic motif of the linker and a proximal hydrophobic pocket within 
the NTKD. The αC-helix then collaborates with phosphorylated Ser221 to 
stabilize NTKD in an active conformation, resulting in synergistic full 
activation of NTKD. Ser221 can be also autophosphorylated by the NTKD. 
Finally, autophosphorylation at the C-terminal Ser737 by NTKD results in 
dissociation of ERK1/2 from the KIM motif and thereby allows active p90RSK 
to associate to many cytoplasmic and nuclear substrates and mediate their 
phosphorylation (Romeo et al. 1012) (Fig. 21). 
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Figure 21. Model of p90RSK activation by sequential phosphorylation. Phosphorylated 
sites are coloured in red and kinases mediating these events are indicated close to them. Active 
kinase domains are coloured in orange. See text for details (Romeo et al. 2012). 
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In order to evaluate p90RSK activation level in a time-course upon 
vandetanib treatment, its phosphorylation was analyzed. p90RSK 
phosphorylation at S380 and Thr359/Ser363 residues was up-regulated in 
resistant compared to parental cells. Then, at 1 hour time point, vandetanib 
(ZD6474) was able to de-phosphorylate p90RSK both in parental and resistant 
cells (Fig. 22). However, 12 hours after treatment, p90RSK phosphorylation 
was completely restored only in resistant cells (Fig. 22). Instead, no difference 
in response to the treatment in parental and resistant cells was noted at T573 
residue (Fig. 22). 
 
 
 
 
 
 
Figure 22. p90RSK is hyper-activated in resistant cells. Parental cells (TT) and two 
representative resistant clones (TT ZD/R CL9, TT ZD/R CL11) were treated as in Fig. 18. 
Total cell lysates (50 µg) were analyzed with anti-phospho p90RSK (pS380, pT/S 359/363 and 
pT573 p90RSK) antibodies. Total p90RSK level was used for normalization. 
   55 
4.2.1 Resistant cells display phosphorylation signature of p90RSK hyper-
activation 
 
To characterize p90RSK function in resistant cells, we checked basal 
levels of phosphorylation, and in response to vandetanib, of bona fide p90RSK 
substrates (Mendoza et al. 2011). p90RSK is a member of AGC protein 
kinases. Because AGC have similar consensus phosphorylation preferences, 
several of them phosphorylate common substrates (Fig. 23). 
 
 
 
 
Figure 23. Pathway convergence and AGC kinase promiscuity. Situations in which the 
same residue is phosphorylated by multiple AGC kinases are indicated. Representative 
substrates of AGC kinase inputs are in light blue. (Modified from Mendoza et al. 2011) 
 
 
 
Thus, parental and two representative resistant clones (TT ZD/R CL10 
and TT ZD/R CL11) were treated or not with 500 nM vandetanib (ZD6474) 
(Fig. 24). Important S6 ribosomal protein phosphorylation sites include 
residues (Ser235/Ser236, and Ser240/Ser244) located within a small, carboxy-
terminal region (Ferrari et al. 1991; Romeo et al. 2012). S6 ribosomal protein is 
   56 
activated by both p70 S6 kinase (p70S6K) and p90RSK (Mendoza et al. 2011) 
(Fig. 23). Its phosphorylation was analyzed at the residues above mentioned by 
immunoblotting. We found that S6 ribosomal protein was basally hyper-
phosphorylated in resistant compared to parental cells. Moreover it was able to 
rapidly rescue (24 hours time points) its phosphorylation upon vandetanib-
treatment only in resistant cells (Fig. 24A). To discriminate p70S6K and 
p90RSK contribution on S6 phosphorylation we compared changes in 
phosphorylation levels of both kinases in response to vandetanib. Kinetics of 
S6 ribosomal protein phosphorylation perfectly paralleled with p90RSK one 
(Fig. 24A and B).   
We also analyzed phosphorylation of another AGC kinase substrate, YB1 
and its response to vandetanib. p90RSK and AKT are both able to directly 
phosphorylate YB1 at Ser102 (Sutherland et al. 2005). To test if the hyper-
activation of p90RSK resulted also in hyper-phosphorylation of YB1, we 
checked Ser102 YB1 phosphorylation in resistant with respect to parental cells. 
Resistant cells displayed a high basal level of Ser102 phosphorylation and 
showed more rapid rescue upon vandetanib treatment (Fig. 24A). At 24 hours 
from treatment, while in parental cells Ser102 of YB1 was still 
dephosphorylated, resistant cells completely rescued Ser102 phosphorylation 
(Fig. 24A). To discriminate the contribution of AKT from p90RSK on YB1 
phosphorylation we followed changes in Ser473 AKT phosphorylation under 
vandetanib treatment. AKT, differently from p90RSK, was not significantly 
changed in parental versus resistant cells and therefore seemed not to be 
involved in sustaining YB1 phosphorylation. 
Then, we compared BAD phosphorylation levels in resistant with respect 
to parental cells. p90RSK is able to phosphorylate BAD at Ser112 (Bonni et al. 
1999; Tan et al. 1999). Phosphorylation kinetics of BAD Ser112 perfectly 
correlated with vandetanib-mediated p90RSK changes (Fig. 24A and B).  
Finally, we wondered whether also the cell-cycle inhibitor p27 Kip1 
(p27), another known p90RSK substrate (Larrea et al. 2009), had increased 
phosphorylation level in resistant cells. p90RSK and AKT are both able to 
directly phosphorylate p27 at T198 (Larrea et al. 2009). Resistant cells 
displayed high levels of p27 T198 phosphorylation; additionally this 
phosphorylation was virtually unaffected by vandetanib treatment. AKT was 
not involved in sustaining p27 phosphorylation; indeed changes in 
phosphorylation of AKT and p27 did not correlate each other under 
vandetanib-treatment (Fig. 24B). Conversely, high levels of p27 
phosphorylation in resistant cells paralleled p90RSK hyper-activation (Fig. 
24A and B). We also analyzed total level of p27. While in parental cells, at 24 
hours from treatment, vandetanib strongly increased the amount of p27, the 
same increment did not occur in resistant cells (Fig. 24A). This was strongly 
suggestive of a potentiated mechanism of p27 degradation through T198 
phosphorylation in resistant versus parental cells.  
All together, these data show that resistant cells feature a phosphorylation 
signature of p90RSK hyper-activation. 
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Figure 24. p90RSK substrates are persistently hyper-phosphorylated in resistant cells. 
Parental (TT) cells and two representative resistant clones (TT ZD/R CL10, TT ZD/R CL11) 
were treated at indicated time points with 500 nM vandetanib (ZD6474). A) Total cell lysates 
(50 µg) were analyzed with anti-phospho S6 (pS235/S236 and pS240/S244), anti-phospho 
BAD (pS112 BAD), anti-phospho YB1 (pS102 YB1), anti-phospho p27 (pT198 p27) and anti 
p27 antibodies. Total tubulin level was used for normalization. B) Total cell lysates (50 mg) 
were analyzed with anti-phospho p70S6K (pS389 p70S6K), anti-phospho p90RSK (pS380 
p90RSK) and anti-phospho AKT (pS473 AKT) antibodies. Total p90RSK level was used for 
normalization. 
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4.2.2 Resistant cells are sensitive to BI-D1870-mediated p90RSK inhibition  
 
We wondered whether inhibition of p90RSK was biologically effective 
in resistant cells. To this aim an inhibitor of p90RSK, the dihydropteridinone 
BI-D1870, was tested. BI-D1870 is a reversible inhibitor that competes with 
ATP by binding to the NTKD ATP-binding site. BI-D1870 is a highly specific 
p90RSK inhibitor; treatment of cells with 10 μM BI-D1870 did not 
significantly inhibit other AGC kinases (Sapkota et al. 2007).  
Thus, parental and resistant cells were exposed for 14 days to different 
doses of BI-D1870. Treatment of parental cells with BI-D1870 reduced 
proliferation with an IC50 of about 2 µM. Consistent with p90RSK activation, 
higher doses of BI-D1870 were required to achieve 50% growth inhibition in 
resistant cells (IC50 of about 4 µM) (Fig. 25A).  
We performed a 1-hour dose-response treatment with BI-D1870 in 
parental and two representative resistant clones (TT ZD/R CL11 and TT ZD7R 
CL 10). As expected, BI-D1870 was able to reduce phosphorylation of 
p90RSK at S221; in parallel we showed a compensatory hyperphosphorylation 
of S380 possibly related to a released feedback mechanism (Dalby et al. 1998) 
(Fig. 25B). 
Thus, we checked phosphorylation events in response to BI-D1870. S6 
ribosomal protein (S6), BAD and YB1 phosphorylations were all sensitive to 
BI-D1870 treatment both in parental and resistant cells. However, while in 
parental cells the phosphorylation of these proteins was strongly inhibited at 4 
µM, consistent with p90RSK hyperactivation, it was necessary 10 µM BI-
D1870 to reach their complete inhibition in resistant cells (Fig. 25B).  
Overall these results show that resistant cells are sensitive to BI-D1870-
mediated p90RSK inhibition. Therefore we hypotize that p90RSK inhibition 
could be really able to trigger vandetanib sensitization in resistant cells. 
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Figure 25. BI-D1870 was effective at inhibiting resistant cells proliferation. A) Cell 
sensitivity to BI-D1820 was assessed by proliferation assay. 2x105 parental (TT) cells and two 
representative resistant clones (TT ZD/R CL10, TT ZD/R CL11) were plated in complete 
medium in the presence of different doses of BI-D1820 and refreshed every 3-4 days. After 14 
days, cells were counted in triplicate: data are reported as % of cell number. In the table are 
reported IC50 values with their respective 95% confidence intervals (CI). B) Parental (TT) 
cells and two representative resistant clones (TT ZD/R CL10, TT ZD/R CL11) were treated for 
1 hr with indicated concentrations of BI-D1820. Total cell lysates (50 µg) were analyzed with 
anti-phospho p90RSK (pS380 and pS221 p90RSK), anti-phospho S6 (pS235/S236 and 
pS240/S244 S6), anti-phospho BAD (pS112 BAD) and anti-phospho YB1 (pS102 YB1) 
antibodies. 
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5.0 DISCUSSION 
 
 
RET RTK plays a role as a driver oncogene in diverse human cancer 
types, such as medullary (MTC) and papillary (PTC) thyroid carcinoma, lung 
adenocarcinoma (LADC), chronic myelomonocytic leukemia (CMML) and 
other myeloproliferative disorders, and Spitz melanoma (Wells et al. 2013; 
Lipson et al. 2012; Ballerini et al. 2012; Wiesner et al. 2014). RET has been 
therefore considered a suitable protein for molecular targeting of these diseases 
(Santoro et al. 2014). Unresectable locally advanced or metastatic MTC, in 
particular, is a challenging clinical problem, and it is very commonly 
associated to genetic lesions causing RET activation (Wells et al. 2013). 
Therefore, among the RET-driven cancers, it has been the first one whereby 
RET TKIs have been exploited. Vandetanib and cabozantinib are two multi-
kinase inhibitors with potent RET activity; both have been tested clinically in 
MTC patients and finally registered for the treatment of advanced disease 
(Wells et al. 2012; Elisei et al. 2013). Both drugs are also being tested in 
patients affected by other RET-driven cancers, such as LADC (Gautschi et al. 
2013; Drilon et al. 2013). Both vandetanib and cabozantinib are type 1 TKI, 
thus binding to the active conformation of the kinase; other type 1 and type 2 
RET TKIs are currently being developed and characterized preclinically 
(Mulligan 2014) 
Targeted cancer therapy has several limitations with resistance to the 
treatment being one of the most challenging ones. Some patients (or preclinical 
model systems) do not respond to therapy (primary resistance) and others 
develop resistance after an initial response (secondary resistance). Both types 
of resistance can be mediated by the drug target itself or by alternative non-
target-mediated mechanisms. Prospective studies in preclinical models have 
the potentiality of anticipating molecular mechanisms that cause resistance in 
vivo and therefore could be useful to devise strategies that can be clinically 
applicable. 
Target-dependent resistance mechanism is illustrated by mutations at the 
gatekeeper residue that is essential for proper TKI binding to the target kinase. 
This is a common mechanism of resistance for a variety of kinases, as 
paradigmatically illustrated by T315I gatekeeper mutation in BCR/ABL CML 
(Gorre et al. 2001; Radich 2014). In principle, this type of resistance can be 
overcome by the use of second line TKIs able to bind the target kinase even 
when modified by the resistance-causing mutation. Again, this concept is well 
illustrated by the use of second and third line ABL inhibitors in CML; even the 
T315I mutation, that has been proved to be recalcitrant to most drugs tested, at 
the end was found to be responsive to ponatinib a recently developed type 2 
TKI (Cortes et al. 2013). Importantly, this concept can be extended to other 
kinase-drug interactions. For instance, we and others have shown that ponatinib 
is a potent RET TKI and able to inhibit the RET-V804M gatekeeper mutant 
(De Falco et al. 2013-Attached at the end of this Dissertation; Mologni et al. 
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2013).  
Non-target dependent resistance mechanisms represent another 
challenging problem and commonly mediate treatment failure. This is typically 
mediated by the activation of alternative pathways that bypass the drug-
mediated block (Sierra et al. 2010). Perhaps, the most stringent example of this 
type of mechanism is that involved in resistance to BRAF kinase inhibitors. 
Instead, melanomas, colon and thyroid cancers escape treatment with BRAF 
inhibitors because they activate RTKs (such as PDGFR, EGFR, HER3) or 
other kinases (such as COT) that overcome drug-mediated block (Lito et al. 
2013; Solit et al. 2014). In the case of RTK activation, MAPK signaling is 
restored parallel to BRAF, because RTK-mediated triggering of RAS drives 
the signal through CRAF, thus bypassing BRAF that remains drug inhibited; in 
the case of COT activation, instead, MAPK signaling is rescued downstream 
from BRAF, due to its COT-mediated activation. Importantly, these resistance 
mechanisms can occur slowly when mutational and therefore requiring the time 
necessary for mutation occurrence and then clonal selection. However, they 
can also occur rapidly because not mediated by DNA lesions but only by 
functional signaling rewiring (adaptation). This is nicely illustrated again by 
lessons learned with BRAF inhibitors, where resistance can be rapidly put in 
place due to drug-induced release from feedback mechanisms. For instance 
melanoma cells can escape BRAF PKIs because they not only results in MAPK 
inhibition but also in inibition of feedback mediators (such as MAPK 
phosphatases or negative signaling adaptors), this in turn rescuing the pathway 
(Lito et al. 2012; Lito et al. 2014). Similarly, in thyroid cancer cells, the use of 
BRAF PKIs results in the suppression of the transcriptional repressors C-
terminal binding protein 1 and 2 which in turn causes upregulated HER3 RTK 
expression (Montero-Conde et al. 2014). Importantly, these studies are being 
rapidly translated into clinical experimentations with drug combinations 
designed to block the resistance driving mechanism (Chapman et al. 2014). 
In this Dissertation, we have addressed molecular mechanisms of 
acquired resistance to vandetanib in cultured MTC cells. We used a RET 
mutant MTC cell line (TT) and selected TT cells able to proliferate also in the 
presence of a vandetanib dose approximately 5-fold higher than that normally 
required to affect proliferation of parental cells. We isolated a mass population 
and several cell clones. The striking similarity of the various isolated resistance 
cells makes it unlikely that their resistance depends on the occurrence of 
independent events and perhaps more likely that vandetanib-resistant sub-
populations already exist within parental cells and be selected during the 
treatment.  
Vandetanib-resistant cells did not display secondary genetic RET 
alterations neither altered RET gene copy number, RNA or protein expression 
levels. However, resistant cells remained addicted to RET as shown by RET 
interference and TKI treatment experiments, though threshold of sensitivity to 
RET inhibition was increased in resistant with respect to parental cells. All 
together, these findings suggested that some altered signaling mechanisms may 
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have been selected in resistant cells able to attenuate effects of RET inhibition 
on cell proliferation, thus allowing cells to escape drug treatment effects. 
We have explored this possibility by analyzing activation state of 
components of the two principal RET signaling pathways PI3K/AKT and 
RAS/ERK, and found that resistant cells featured a persistent hyper-activation 
of p90RSK, a serine/threonine kinase of the RAS/ERK pathway.  
Functional studies have implicated p90RSK in the regulation of diverse 
cellular processes, including transcription, translation, survival, cell-cycle 
progression and migration. p90RSK has been linked to tumorigenesis. 
p90RSK1 and p90RSK2 are overexpressed in breast and prostate cancer (Serra 
et al. 2013). Moreover p90RSK3 and p90RSK4 can mediate resistance to PI3K 
inhibitors in breast cancer cells (Serra et al. 2013). Interestingly, p90RSK4 has 
been implicated in sunitinib resistance (Bender and Ullrich. 2011). p90RSK 
functions through phosphorylation of targets including S6 ribosomal protein, 
BAD, YB1 and p27Kip1, among others (Serra et al. 2013; Aronchik et al. 
2014). Accordingly, vandetanib-resistant cells displayed a phosphorylation 
signature compatible with p90RSK hyper-activation and this signature was 
consistent with the increase in the transformed phenotype (aggressive 
morphology, increased proliferation and tumorigenicity and capability of 
proliferating in semisolid medium) featured by vandetanib-resistant cells. 
Increased phosphorylation of S6 ribosomal protein correlates with an increase 
in translation of mRNA transcripts encoding proteins involved in cell cycle 
progression, as well as ribosomal proteins and elongation factors necessary for 
protein translation (Peterson et al. 1998). Interestingly, it has been previously 
demonstrated the involvement of S6 phosphorylation in primary MTC and 
lymph node metastases (Tamburrino et al. 2012).  BAD is a proapoptotic 
member of the Bcl-2 family that promotes cell death by displacing BAX from 
binding to Bcl-2 and Bcl-xL (Yang et al. 1995). Survival factors inhibit the 
pro-apoptotic activity of BAD by activating intracellular signaling pathways 
that result in its phosphorylation at Ser112 and Ser136 (Zha et al. 1998). Thus, 
increased BAD phosphorylation may allow vandetanib-resistant cells to escape 
apoptosis. Phosphorylation-mediated activation of YB1 transcription factor 
activates genes associated with proliferation and cancer, such as cyclin A, 
cyclin B1, matrix metalloproteinase-2 (MMP-2), and the multi-drug resistance 
1 (MDR1) gene (Jurchott et al. 2003) while repressing genes associated with 
cell death, including the cell death-associated receptor FAS and the p53 tumor 
suppressor gene (Lasham et al. 2000). Finally, p27 is a member of the Cip/Kip 
family of cyclin-dependent kinase inhibitors. Expression levels of p27 are 
upregulated in quiescent cells and in cells treated with negative cell cycle 
regulators. Downregulation of p27 can be induced by treatment with mitogens; 
this involves phosphorylation of p27 at residues such as T157 and T198 
followed by nuclear export and degradation by the ubiquitin-proteasome 
pathway (Lloyd et al. 1999; Larrea et al 2009). Thus, increased 
phosphorylation of p27 may mediate evasion by cell growth arrest exerted by 
vandetanib-resistant cells. 
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To validate p90RSK role in vandetanib-resistance, we tested efficacy of 
BI-D1870, an ATP-competitive inhibitor of p90RSK NTKD. Our results 
showed that resistant cells are sensitive to BI-D1870-mediated p90RSK 
inhibition. Based on these results we want to test whether BI-D1870 in 
combination with vandetanib, is able to revert resistance in resistant cells. We 
hypotize that BI-D1870 treatment could restore vandetanib-IC50 value of 
resistant cells to a vandetanib-IC50 value similar to that of parental cells. 
Consistently we hypotize that p90RSK downstream signaling could be affected 
by vandetanib and BI-D1870 combined treatment. 
The molecular mechanism driving p90RSK upregulation in vandetanib-
resistant cells is still unknown. No point mutation was found by next 
generation sequencing in the four p90RSK family members (data not shown). 
Moreover, no significant increase in p90RSK family members expression was 
seen in vandetanib-resistant cells at both protein and RNA level (data not 
shown). Rather, we observed increased basal phosphorylation levels of 
p90RSK at CTKD-dependent Ser380 (in the linker region) and at PDK1-
dependent Ser221 (in the NTKD) in resistant cells, whereas the MAPK-
dependent Thr573 (in the CTKD) phosphorylation level was unchanged with 
respect to parental cells.  
These findings suggest the possibility that some altered signaling 
mechanisms may have occurred in vandetanib-resistant cells to mediate 
p90RSK upregulation and consequently attenuate response to RET TKI. 
Possible mechanisms are depicted in Fig. 26. 
One possibility is that an unidentified kinase phosphorylates p90RSK on 
Ser380 in vandetanib-resistant cells bypassing canonical MAPK-mediated 
activation of the CTKD (Fig. 26). In favor of our hypothesis, Cohen et al. 
(2007) showed that in certain cellular contexts (for example, LPS-stimulated 
macrophages) an unidentified kinase bypassed the CTKD requirement and 
phosphorylated p90RSK at Ser380, thus driving activation of the NTKD. 
According to this possibility, saturating concentrations of FMK (an inhibitor of 
CTKD) failed to inhibit Ser380 phosphorylation in vandetanib-resistant cells 
(data not shown), supporting the possibility that Ser380 phosphorylation occurs 
in a CTKD-independent manner. Consistently, Zaru et al. (2007) demonstrated 
that in dendritic cells (DCs), phosphorylation of Ser380 was incompletely 
suppressed by PD184352 (MEK inhibitor), which suggested that the ERK-
activated CTKD of p90RSK could be bypassed. Ser380 phosphorylation was 
completely blunted, however, in the presence of inhibitors of ERK and p38. 
Notably, Ser380 phosphorylation persisted in the presence of FMK, consistent 
with the possibility that a second pathway of p90RSK activation may exist 
(Zaru et al. 2007). Similarly, preliminary data show that in vandetanib-resistant 
cells a MEK inhibitor (U0126) was not able to completely inhibit p90RSK, still 
pointing to a partially MAPK-independent mechanism of p90RSK activation 
(data not shown). 
However, we would favor a second possibility, e.g. that p90RSK 
upregulation is sustained by the downregulation of some negative feedback 
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mechanisms normally in place to restrain p90RSK signaling. Indeed, we 
observed that upon 1 hour treatment vandetanib was able to mediate p90RSK 
dephosphorylation in both parental and resistant cells; however, at 12 hours 
treatment p90RSK phosphorylation was promptly restored only in resistant 
cells, a phenotype that suggests the release from some feedback mechanisms. 
Inactivation of p90RSK involves NTKD-catalyzed phosphorylation Ser737. 
This event decreases the affinity of ERK for p90RSK, preventing reactivation 
of p90RSK after that phosphatases have dephosphorylated the activating sites. 
One of the phosphatases involved in p90RSK inactivation is PP2Cδ, a member 
of the PP2C family protein of metal-dependent phosphatases. PP2Cδ is 
recruited to the activated p90RSK and forms a complex with its NTKD. The 
binding of p90RSK to PP2Cδ then induces a conformational change in the 
latter, allowing ERK to phosphorylate PP2Cδ, leading to dissociation of the 
p90RSK–PP2Cδ complex. However, no difference in response to the treatment 
between parental and resistant cells was noted at the level of MAPK-dependent 
T573 residue. Therefore, if a perturbed negative feedback mechanism is 
involved, this should occur at the level of S380 phosphorylation or the NTKD 
(Fig. 26). 
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Figure 26. Schematic representation of adaptive mechanism of secondary resistance of 
MTC cells to RET TKI involving p90RSK hyper-activation. 
 
 
 
Whatever the mechanism, increase of a positive regulator or decrease of 
a negative one, this should be fixed at the genomic or epigenomic level in 
resistant cells since resistance was irreversible and maintained also upon 
several months (and therefore cell duplications) of vandetanib deprivation.  
In conclusion, our data demonstrate that vandetanib-resistant cells were 
sensitive to BI-D1870 inhibitor, thereby suggesting the use of p90RSK 
inhibitors in combination with RET TKIs as a possible strategy to overcome 
resistance and possibly prevent resistance in MTC cells. This study also 
suggests a number of possible read-outs, including p90RSK, BAD, YB1, S6 
and p27 phosphorylation levels, to verify whether the mechanism identified in 
vitro in TT cell line is also involved in clinical samples in MTC patients who 
develop resistance to RET TKI treatment. 
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6.0 CONCLUSIONS 
 
 
In conclusion, here we show that MTC cells develop in vitro irreversible 
resistance to chronic RET TKI treatment. Resistant cells featured a more 
agressive phenotype with respect to parental cells. We excluded that genetic 
changes in RET contributed to resistance. Instead, resistant cells featured 
hyper-activation of p90RSK, a kinase of the MAPK signaling pathway, and a 
phosphorylation protein signature typical of p90RSK hyper-activation. Finally 
resistant cells are sensitive to p90RSK blockade suggesting that p90RSK 
targeting may represent a strategy to overcome resistance to RET TKIs. 
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Context: The RET tyrosine kinase encoding gene acts as a dominantly transforming oncogene in
thyroidcarcinomaandothermalignancies. Ponatinib (AP24534) is anoralATP-competitive tyrosine
kinase inhibitor that is in advanced clinical experimentation in leukemia.
Objective: We tested whether ponatinib inhibited RET kinase and oncogenic activity.
Methods: Ponatinib activity was studied by an in vitro RET immunocomplex kinase assay and
immunoblotting. The effects of ponatinib on proliferation of human TT, MZ-CRC-1, and TPC-1
thyroid carcinomacells,whichharborendogenousoncogenicRETalleles, andofNIH3T3 fibroblasts
transfected with oncogenic RET mutants were determined. Ponatinib activity on TT cell xeno-
grafted tumors in athymic mice was measured.
Results: Ponatinib inhibited immunopurified RET kinase at the IC50 of 25.8 nM (95% confidence
interval [CI] 23.15–28.77 nM). It also inhibited (IC50 33.9 nM; 95%CI 26.41–43.58 nM) kinase
activity of RET/V804M, a RET mutant displaying resistance to other tyrosine kinase inhibitor.
Ponatinib blunted phosphorylation of point-mutant and rearranged RET-derived oncoproteins
and inhibitedproliferationofRET-transformedfibroblasts andRETmutant thyroid carcinomacells.
Finally, after 3 weeks of treatment with ponatinib (30 mg/kg/d), the volume of TT cell (medullary
thyroid carcinoma) xenografts was reduced from 133 mm3 to an unmeasurable size (difference
133 mm3, 95% CI  83 to 349 mm3) (P  .001). Ponatinib-treated TT cell tumors displayed a
reduction in the mitotic index, RET phosphorylation, and signaling.
Conclusions: Ponatinib is a potent inhibitor of RET kinase and has promising preclinical activity in
models of RET-drivenmedullary thyroid carcinoma. (J Clin Endocrinol Metab 98: E811–E819, 2013)
Oncogenic conversion of the RET (REarranged duringTransfection) transmembrane receptor tyrosine ki-
nase (RTK) is associatedwith several humanmalignancies
(1). Virtually all (98%) cases of multiple endocrine neo-
plasia (MEN) type2 (MEN2), featuringmedullary thyroid
carcinoma (MTC), are caused by germline activatingRET
point mutations and approximately 50% of patients with
sporadic MTC bear somatic RET mutations, most com-
monlyM918T (1–3).A fraction (5%–40%)of cases of the
most common type of thyroid cancer, papillary thyroid
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carcinoma (PTC), result from chromosomal inversions or
translocations that generate hybrid transforming genes,
termed RET/PTC. RET/PTC genes are composed of the
TK-encoding domain of RET fused to the promoter and
5-terminal region of unrelated genes, most commonly
CCDC6 (RET/PTC1) and NCOA4 (RET/PTC3) (4).
RET gene rearrangements have been recently demon-
strated to play an important role in a subset of cases of
non–small cell lung cancer (5–7) and chronicmyelomono-
cytic leukemia (8), up-regulated RET expression is asso-
ciated with several malignancies, including neuroblas-
toma (9), pancreatic cancer (10), and breast cancer (11).
Smallmolecule tyrosine kinase inhibitors (TKIs) of var-
ious chemical classes inhibiting RET tyrosine kinase (TK)
are in clinical development (12, 13). The clinically most
advanced RET TKIs are vandetanib (ZD6474) and cabo-
zantinib (XL184), both recently registered for the treat-
ment of locally advanced or metastatic MTC (14–17).
Ponatinib (AP24534) is an oral multitargeted TKI that
potently inhibits BCR-ABL and additional protein ty-
rosine kinases, including SRC-related kinases, and mem-
bers of the III/IV/VRTKclasses, such as FLT3 (fms-related
tyrosine kinase 3), KIT, FGFR1 (fibroblast growth factor
receptor 1), PDGFR (platelet-derived growth factor re-
ceptor ), and VEGFR-2/KDR (vascular endothelial
growth factor [VEGF] receptor-2/kinase insert domain re-
ceptor) (18–20). Unlike vandetanib, ponatinib is a class 2
inhibitor, eg, a TKI that preferentially binds the inactive
conformation of the kinase (21). Ponatinib inhibits both
native and mutant forms of BCR-ABL, including the
T315I gatekeeper mutant, which is refractory to imatinib
and was highly active in patients with Ph-positive leuke-
miaswith resistance to TKIs (Ref. 22 andNCT01207440,
www.clinicaltrials.gov).
Here, we provide evidence that ponatinib is a novel
potent RET TKI that might be suited for treatment of
RET-driven malignancies, such as MTC.
Materials and Methods
Compounds
Ponatinib (AP24534) was provided by ARIAD Pharmaceuti-
cals, Inc (Cambridge,Massachusetts) and dissolved as described in
SupplementalMethodspublishedonTheEndocrineSociety’s Jour-
nals Online web site at http://jcem.endojournals.org.
Cell cultures
Human embryonic kidney 293 cells were used for transient
transfections as described in Supplemental Methods. NIH3T3
and RAT1 fibroblasts stably expressing the oncogenic RETmu-
tantswere described previously (14, 23, 24). TheTT cell linewas
derived from a sporadicMTC (25) and harbors a cysteine 634 to
tryptophan (C634W) RET mutation (26) as well as a tandem
duplication of the mutated RET allele (27). MZ-CRC-1 cells
were derived from a malignant pleural effusion from a patient
with metastatic MTC (28) and bear the RET substitution of
threonine918 formethionine (M918T) (15).HumanTPC-1cells
harbor the RET/PTC1 rearrangement (14); TPC-1 and BCPAP
PTC cells were authenticated byDNA short tandem repeat anal-
ysis (29).Nthy-ori 3-1 is a human thyroid follicular epithelial cell
line immortalized by the simian virus 40 large T gene. Cell lines
were cultured, and cell proliferation assays were performed as
described in Supplemental Methods.
Plasmids
Plasmidswere describedpreviously (23, 24, 30) as reported in
Supplemental Methods.
Protein Studies
Protein studies were performed as described in Supplemental
Methods.
In vitro kinase assay
The in vitro RET autophosphorylation assay was performed
as described elsewhere (31) and reported in Supplemental
Methods.
Tumorigenicity assay
Animal studies were performed according to institution-ap-
proved protocols in compliance with the Italian Ministry of
Health Guide for the Care and Use of Laboratory Animals. TT
cells (5  107) were injected sc into the right dorsal portion of
female BALB/c nude (nu/nu) mice.When tumor volume reached
100 to 150mm3 (experiment 1) or 700 to 750mm3 (experiment
2) (after approximately 30 or 40 days from injection, respec-
tively), animalswere randomly assigned to receive byoral gavage
vehicle (9 and 6 mice in experiment 1 and 2, respectively) or
ponatinib (30 mg/kg/d) (10 and 6 mice in experiment 1 and 2,
respectively) for 21 or 7 days in experiment 1 and 2, respectively.
Tumor size was assessed by calipers at regular intervals, and
tumor volume was calculated according to the formula (L 
W2)/2, where L is length andW is width of tumor. Tumors from
experiment 2 were excised and divided in 2 parts. Half the tissue
was snap-frozen in liquid nitrogen and used for protein extrac-
tion. The other half was fixed overnight in neutral buffered for-
malin and processed for histological examination. In another
experiment (experiment 3), a lower dose of ponatinib (20 mg/
kg/d, 5 doses in 7days)was administered (for 3 consecutive days,
interrupted for 2 days and administered again for 2 consecutive
days) to tumor (400 mm3)–bearing mice (n  8); vehicle was
used in control mice (n  7). Finally, for target inhibition ex-
periments (experiment 4), another group of nude mice (n  6)
were injected with 5  107 TT cells. After approximately 40
days, when tumors measured 500 mm3, animals were ran-
domly assigned to receive per os a single dose of ponatinib (30
mg/kg) (n  4) or vehicle (n  2). Then 5 hours after dosing,
tumors were excised, and RET protein phosphorylation was de-
termined by immunoblot.
Histological examination and
immunohistochemistry
Tumor samples from experiment 2 were fixed in 10% neu-
tral-buffered formalin, embedded in paraffin, and processed for
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hematoxylin and eosin staining and immunohistochemical anal-
ysis as described in Supplemental Methods.
Statistical analysis
Statistical analysiswas performed as described in Supplemen-
tal Methods.
Results
Ponatinib inhibits RET kinase and RET
phosphorylation in intact cells
We studied whether ponatinib (AP24534) was able to
inhibit in vitro RET enzymatic activity. To this aim, RET/
C634R (Figure 1A), the oncogenic RET mutant most fre-
quently found inMEN2A,was used (1). RET/C634Rpro-
tein was immunoprecipitated and incubated in kinase
buffer containing [-32P]ATP in the
presence of different concentrations
of the drug. Samples were separated
by SDS-PAGE; gels were dried and
exposed to phosphorimaging to
measure the extent of RET protein
autophosphorylation. The average
results of 3 independent assays
showed that ponatinib was a potent
RET TKI, inhibiting RET kinase
with an IC50 of 25.8 nM (95% con-
fidence interval [CI] 23.15–28.77)
(Figure 1B).
We tested whether ponatinib ac-
tivity against RET enzyme in vitro
translated into a reduction of phos-
phorylation and signaling of onco-
genic RET proteins in intact cells.
RET point mutants depicted in Fig-
ure 1A and Supplemental Figure 1
were selected from RET mutation
databases (www.arup.utah.edu/
database/MEN2/MEN2_welcome.
php and www.sanger.ac.uk/genet-
ics/CGP/cosmic/). All these mutants
have been associated to familial or
sporadic MTC (2, 3). C634R has
been described above; M918T is the
RET mutant most frequently found
in MEN2B and sporadic MTC.
A883F is associated with cases of
MEN2B that are negative for
M918T. V804 and Y806 mutants
were reported previously to be re-
fractory to vandetanib and other
TKIs (24, 30). We also tested
ponatinib activity against most com-
mon RET-derived fusion oncogenes associated with PTC
(Figure 1A). Human embryonic kidney 293 cells were
transiently transfected with the various RET constructs,
and, after 48 h, treated for 60 minutes with ponatinib at
the indicated doses and harvested. Immunoblotting with
phospho-specific antibodies was applied to detect RET
protein phosphorylation at 2 sites: Y905, located in the
kinase activation loop, and Y1062, a multidocking site
involved in RET downstream signaling. Phosphorylation
of SHC, a RETTK substrate, was studied as well (32, 33).
Ponatinib efficiently inhibited phosphorylation of the
RETmutants tested and SHCwith an IC50 of 5 to 100 nM
(Figure 1C and Supplemental Figure 1). RET/L790F and
RET/Y791F (Supplemental Figure 1) were slightly more
sensitive to ponatinib than the other mutants, whereas
Figure 1. In vitro inhibition of RET kinase by ponatinib. A, Schematic representation of RET
protein structure, RET mutants, and rearrangements used in this study. SP, signal peptide; EC,
extracellular domain; Cys, cysteine-rich domain; TM, transmembrane domain; JX, juxtamembrane
domain TK, tyrosine kinase domain; X, RET fusion partners. B, In vitro RET autophosphorylation
assay. Protein extracts from RAT1-RET/C634R cells were immunoprecipitated with anti-RET and
subjected to an immunocomplex kinase assay in the presence of [-32P]ATP. Ponatinib or vehicle
(dimethyl sulfoxide) was added to the reaction mixture to reach the indicated concentrations.
Reaction products were separated by SDS-PAGE and autoradiographed. Phosphorimaging was
used to quantify the results. Each point represents the mean value for 4 independent
determinations and is plotted as a percentage of residual activity; error bars represent 95% CIs.
The IC50 value is indicated. C, Inhibition of RET and oncogenic RET mutant phosphorylation and
signaling by ponatinib. Serum-starved (18-hours) cells, transfected with the indicated RET
constructs, were treated with different concentrations of drug for 1 hour; 50 g of total cell
lysates were immunoblotted with antibodies specific for phospho-RET/Y905,
phospho-RET/Y1062, or phospho-SHC. Equal gel loading was determined by using an anti-RET
antibody. Data are representative of 3 independent experiments.
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RET/V804M, RET/V804L, RET/Y806C, RET/A883F
(Figure 1C), and RET/E768D and RET/D898V (Supple-
mental Figure S1) were less sensitive but were still inhib-
ited at 50 to 100 nM. Accordingly, an immunocomplex
kinase assay showed that IC50 of ponatinib for RET/
V804M in vitro kinase activity was 33.9 nM (95% CI 
26.41–43.58) (Supplemental Figure 2). Wild-type RET
protein undergoes autophosphorylation when overex-
pressed, and such phosphorylation was inhibited by
ponatinib (Figure 1C).
Ponatinib efficiently inhibits RET-mediated cancer cell
proliferation
We asked whether ponatinib affected RET-driven cell
proliferation. To this aim, proliferation assays were per-
formed by using different doses of compound onNIH3T3
cells transformed by RET/C634Y or RET/M918T mu-
tants. As controls, cells transformed by the unrelated
HRAS/G12V oncogene or parental NIH3T3 cells were
used. Oncogene (RET and HRAS) expression renders
NIH3T3 cells serum-independent for growth. At 6 days, 5
nMponatinib strongly reduced cell proliferationdrivenby
RET/C634Y (from 24  103% [95% CI  19  103%–
29 103%] to 16 103% [95%CI 13 103%–19
103%]) and RET/M918T (from 30  103% [95% CI 
29  103%–31  103%] to 19.5  103% [95% CI 
17.5 103%–21.5 103%]) (P .001). Conversely, up
to 50 nM ponatinib exerted no sig-
nificant (P  .05) growth inhibition
of parental and HRAS-transformed
cells (Figure 2 and Supplemental
Results).
We measured the antiprolifera-
tive effects of ponatinib in human
thyroid cancer cells endogenously
expressing oncogenic RETmutants.
For this experiment, we selected TT
(MTC cells harboring the RET/
C634W mutation), MZ-CRC-1
(MTC cells harboring the RET/
M918Tmutation), and TPC-1 (PTC
cells harboring the RET/PTC1 rear-
rangement) cells. As controls, we
used BCPAP cells (PTC cells harbor-
ing the BRAF/V600E mutation and
no RETmutation) and Nthy-ori 3-1
cells (nontransformed thyrocytes
immortalized by the simian virus 40
large T gene). Figure 3A shows that
ponatinib had potent effects in RET-
positive but not in RET-negative
cells. At 4 days, 5 nM ponatinib re-
duced proliferation of TT cells (from
91% [95%CI 68%–114%] to 9% [95%CI14%–
32%]) (P .05) andTPC-1 cells (from2900%[95%CI
2487%–3313%] to 1644%[95%CI1592%–1696%])
(P  .001) (Figure 3A). Moreover, 5 nM ponatinib (4
days) reduced thenumberofMZ-CRC-1 cellswith respect
to the vehicle control (from 33% [95% CI 13%–53%)
to10%[95%CI2%to18%]) (P .05), therefore
not only blocking cell growth but also exerting slight cy-
totoxicity (Figure 3A). Notably, at 4 days, up to 50 nM
(BCPAP) or 10 nM (Nthy-ori 3-1) ponatinib did not exert
significant (P  .05) growth inhibition in RET-negative
cells. At 50 nM, ponatinib reduced Nthy-ori 3-1 prolifer-
ation by approximately 36% (P  .01) (Figure 3A).
MTC cells show a slow proliferation rate in culture.
Thus, we performed additional growth curve experiments
by extending exposure to the drug up to 2 weeks. In these
conditions, a ponatinib dose as small as 1 nM exerted
significant growth inhibition. Indeed, TT cells treated (15
days) with vehicle or with 1 nM ponatinib numbered
1635  103 (95% CI  1472  103–1797  103) and
103.5  103 (95% CI  84.8  103–122.2  103), re-
spectively (P  .001), and MZ-CRC-1 cells treated (16
days) with vehicle or with 1 nM ponatinib numbered
1362  103 (95% CI  1192  103–1531  103) and
160.8  103 (95% CI  114.2  103–207.5  103), re-
spectively (P  .001) (Figure 3B).
Figure 2. Inhibition of RET-mediated proliferation by ponatinib. NIH3T3-derived cell lines were
incubated with vehicle or the indicated ponatinib doses in 5% and 2.5% calf serum (parental
and transfected cells, respectively) and counted at 6 days. Cell proliferation was calculated as
percent change with respect to the initial cell number: each point represents the mean value for
3 dishes, and error bars represent 95% CIs. Statistical significance was determined by 1-way
ANOVA with the Bonferroni multiple comparison test.
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Proteins were harvested, and RET phosphorylation
was determined by immunoblot at 13 (TT) or 14 (MZ-
CRC-1) days of ponatinib treatment. Consistent with
growth inhibition, RET phosphorylation clearly de-
creased at ponatinib doses as small as 1 nM (Figure 3C).
In parallel, ponatinib also decreased phosphorylation of
several proteins that function in the RET signaling cas-
cade, such as SHC, PLC (phospholipaseC),MAPK (mi-
togen-activated protein kinase; extracellular signal-regu-
lated kinase [ERK]), AKT, and ribosomal S6 protein
(Figure 3C). The ponatinib dose (1 nM) is smaller that that
able to achieve an efficient reduction of RET phosphory-
lation after 1 hour of treatment (Figure 1C) and to inhibit
RET kinase in vitro (Figure 1B). This result might be ex-
plained by the fact that ponatinib is a type 2 kinase inhib-
itor that preferentially binds to the inactive conformation
of the kinase, a conformation that, in intact cells, might be
fostered by chronic exposure to the drug (21).
Ponatinib is a multitargeted agent and its growth in-
hibitory effects can be mediated by the concurrent inhi-
bition of additional tyrosine kinases other than RET.
Among the additional ponatinib targets (18), TT cells did
not show detectable phosphorylation of ABL (Y245)
(Supplemental Figure 3B), Lyn (Y397), Lck (Y394), Fyn
(Y420), andYes (Y426)kinases (datanot shown). Instead,
pp60SRC (Y416) showed detectable phosphorylation in
TT cells; however, at 1 hour of treatment, phospho-Y416-
SRCwas not inhibited by 10 nMponatinib (Supplemental
Figure 3B) but only by 50 nMponatinib (data not shown).
To explore additional ponatinib targets,we tested levels of
Figure 3. Inhibition of RET-mediated growth and signaling by ponatinib in human thyroid cancer cells. A, The indicated cell lines were incubated
with vehicle or different doses of ponatinib in 2.5% (BCPAP, Nthy-ory 3-1, TPC-1, or MZ-CRC-1) or 4% (TT) serum and counted at 4 days. Cell
proliferation was calculated as percent change with respect to initial cell number: each point represents the mean value for 3 dishes, and error bars
represent 95% confidence intervals. B, MZ-CRC-1 (2.5% serum) or TT (4% serum) were incubated with the indicated doses of ponatinib or vehicle
and counted at different time points. Each point represents the mean value for 3 dishes, and error bars represent 95% confidence intervals. C, TT
and MZ-CRC-1 cells were treated with vehicle or ponatinib for 13 or 14 days, respectively. Cell lysates (50 g) were immunoblotted with the
antibodies indicated. Data are representative of 3 independent experiments.
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phosphorylation of 42 different RTKs in TT and MZ-
CRC-1 cells. Besides RET, both cell lines expressed de-
tectable phosphorylation of additional RTKs such as
EGFR (epidermal growth factor receptor), VEGFR-2/
KDR (VEGF receptor 2), InsR (insulin receptor), IGF1R
(insulin-like growth factor 1 receptor) andDTK (TYRO3)
(Supplemental Figure 3A). Among them, VEGFR-2/KDR
is a known ponatinib target (18). Accordingly, we ob-
served by immunoblot that ponatinib (10 nM) decreased
VEGFR-2/KDR (but not EGFR) phosphorylation (Sup-
plemental Figure 3B). At 2 weeks of treatment, ponatinib
inhibited VEGFR-2/KDR phosphorylation in TT and
MZ-CRC-1 cells even at a dose as small as 1 nM (Figure
3C). Thus, it is possible that ponatinib growth inhibitory
effects inMTCcells aredue to combined inhibitionofRET
and VEGFR-2/KDR.
Ponatinib inhibitsRET-mediated tumorgrowth inmouse
xenografts
We sought to determine whether ponatinib had inhib-
itory effects invivoagainstRET-dependent tumorgrowth.
In previous studies usingBCR-ABLT315I transducedBa/F3
cells, daily oral ponatinib dosing of 10 and 30 mg/kg
caused suppression of tumor growth and 50mg/kg caused
tumor regression (18). At a dose of 30 mg/kg, plasma
ponatinib levels in mice were reported to reach 782 nM at
2 hours and then decline to 561 nM at 6 hours and 8 nM
at 24 hours postdose (18). Therefore, plasma levels ex-
ceeding the in vitro IC50 values for RET can be sustained
in mice for at least 6 hours with a 30 mg/kg oral dose.
Thus, we selected a 30 mg/kg dose to obtain proof of the
concept that ponatinib canobstruct in vivoRET-mediated
tumor growth. We injected nude mice with 5  107 TT
cells. After approximately 30 days, when tumors mea-
sured100 to 150mm3, animalswere randomly assigned
to receive by oral gavage ponatinib (30 mg/kg/d) (n 10)
or vehicle (n 9) 5 days/wk for 3 weeks. Tumor diameter
was monitored with calipers. Treatment with ponatinib
strongly reduced tumor growth (P  .001) (Figure 4A).
After 3 weeks of ponatinib treatment, the volume of TT
cell xenografts was reduced from 133 mm3 (95% CI 
93–173 mm3) to unmeasurable size, whereas in vehicle-
treated mice, mean tumor volume increased from 136
mm3 (95% CI  90–181 mm3) to 541 mm3 (95% CI 
377–704 mm3). Effects were very rapid and reduced tu-
mor burden was statistically significant (P .05) as early
as at day 8 of treatment. According to previous reports
(18), we noted no signs of overt toxicity in mice with a
maximal decrease in body weight 10% (untreated vs
treated, P .05) (Supplemental Figure 4A), no change in
animal behavior, and, only occasionally, a modest skin
rash on the back and scalp.
Figure 4. Antitumorigenic effects of ponatinib in TT cell xenografts. A,
TT cells (5 107/mouse) were inoculated sc into the right dorsal portion
of BALB/c nude mice. When tumors measured100 to 150 mm3,
animals were randomly assigned to receive ponatinib (30 mg/kg/day; n
10) or vehicle (n 9) by oral gavage. Treatment was administered for 5
consecutive days/wk for 3 weeks (day 0 is the treatment starting day).
Tumor diameters were measured with calipers, and tumor volumes were
calculated. Error bars represent 95% CIs. P values for the comparisons (at
the different time points) between compound and vehicle are reported.
Statistical significance was determined by 1-way ANOVA with the Tukey-
Kramer multiple comparison test. B, TT cells (5 107/mouse) were
inoculated as described in A. When tumors measured650 to 700 mm3,
animals were randomly assigned to receive ponatinib (30 mg/kg/day; n
6) or vehicle (n 6) by oral gavage. Treatment was administered for 3
consecutive days, interrupted for 2 days, and administered again for
another 2 consecutive days (day 0 is the treatment starting day). Tumor
diameters were measured with calipers, and tumor volumes were
calculated. Error bars represent 95% CIs. P values for the comparisons (at
the different time points) between compound and vehicle are reported.
Statistical significance was determined by 1-way ANOVA with the Tukey-
Kramer multiple comparison test. C, Protein lysates (50 g) of the 7-day
vehicle-treated (NT) or ponatinib-treated (T) xenografts were subjected to
immunoblotting with the indicated antibodies.
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To perform biochemical and histological studies, we
treated a set of TT cell-induced large tumors (650–700
mm3) for a short time period (7 days). After 7 days of
ponatinib (30 mg/kg/d) treatment, the average volume of
xenografts (n 6)was reduced from736mm3 (95%CI
335–1138 mm3) to 237 mm3 (95%CI 155–320 mm3),
whereas in vehicle-treated mice (n  6) mean tumor vol-
ume increased from 587 mm3 (95%CI 268–906 mm3)
to 901mm3 (95%CI 545–1257mm3) (P .05) (Figure
4B). In addition, no significant reduction in the weight of
the mice (untreated vs treated, P  .05) was observed in
these mice (Supplemental Figure 4B). At 7 days, tumors
were excised, andproteinswereharvested fromponatinib-
treated and vehicle-treated tumors. RET and RET-signal-
ing component (SHC, PLC, and ribosomal S6) phos-
phorylation was decreased upon ponatinib treatment;
MAPKphosphorylationwas decreased in all but 1 sample
(Figure 4C). On histological examination, ponatinib-
treated tumors featured a reduction in tumor cell density
and diffuse fibrosis (P .001) (Figure 5 and Supplemental
Table 1). No significant change in the extent of necrosis
(Supplemental Table 1) and in the density of microvessels
(data not shown) was observed. Moreover, ponatinib
treatment caused a reduction in the proliferative index,
with a strong reduction in Ki-67 reactive cells (Figure 5
andSupplementalTable 1) andmitotic index (Supplemen-
tal Table 1). Treated tumors showed also a small, albeit
significant (P .001), increase in tumor cell deathwith an
increased fraction of cells immunoreactive for cleaved
caspase 3 (Supplemental Table 1).
Finally, for target inhibition experiments, we injected
another group of nudemice (n 6) with 5 107 TT cells.
After approximately 40 days, when tumors measured
500mm3, animalswere randomly assigned to receive by
oral gavage a single dose of ponatinib (30 mg/kg) (n 4)
or vehicle (n  2). As early as 5 hours after dosing, RET
protein phosphorylation was clearly decreased (Supple-
mental Figure 5).
Furthermore, a lower (66%) dose of ponatinib (20mg/
kg/d, 5 doses in 7 days) was also able to cause a significant
reduction (P  .05) of TT cell-induced tumor volume (in
treatedmice [n8] averagevolumewas reduced from440
mm3 [95% CI  244–636 mm3] to 88 mm3 [95% CI 
51–127 mm], whereas in vehicle-treated mice [n  7],
mean tumor volume increased from 382 mm3 [95%
CI  183–580 mm3] to 635 mm3 [95% CI  305–964
mm3]) (P  .05) (Supplemental Figure 6A). In parallel,
RET protein phosphorylation was decreased (Supple-
mental Figure 6B).
Discussion
RET genetic alteration is involved in several human ma-
lignancies, including PTC (RET/PTC gene rearrange-
ments) (4), MTC (RET point mutations) (1–3), lung ad-
enocarcinoma (KIF5B/RET and RET/PTC1) (5–7), and
chronic myelomonocytic leukemia (BCR-RET and
FGFR1OP-RET) (8). Thus, RET kinase is an appealing
molecular target for cancer therapy. Several RET TKIs
Figure 5. Histopathologic examination of ponatinib effects in TT cells xenografts. Top, Hematoxylin and eosin (H&E) staining was performed on
vehicle- and ponatinib-treated xenografts of B. Representative images of 4 independent samples are shown. In ponatinib-treated samples (T), the
presence of diffuse fibrosis as fibrous bands around nests of neoplastic cells was observed (10 and 20 magnification). Bottom, Ki-67
immunohistochemical staining of vehicle-treated xenografts (NT) compared with ponatinib-treated xenografts (T) (10 magnification). Insets: 20
magnification.
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have been identified, and their efficacy has been studied in
preclinicalmodels and, in some cases, in clinical trials. The
most advanced drugs, vandetanib (ZD6474) and cabo-
zantinib (XL184), target RET as well as other receptors
including VEGFR-2/KDR (in the case of both) and EGFR
(in the case of vandetanib) (12, 13). A lesson learned from
other neoplasia is that it is important to have available
alternative andmore potent TKIs if the first inhibitor fails
or patients develop resistance. In some instances, resis-
tance can be mediated by mutations in the target kinase
that impair drug binding, as in the case of mutations tar-
geting the “gatekeeper” residue, positioned at the gate of
the ATP binding pocket (22).
Here, we show that ponatinib (AP24534) is a potent
RET kinase inhibitor at clinically achievable drug levels.
The IC50ofponatinib for the isolatedRETkinasewas25.8
nM and in intactMTC cells, when the treatment was pro-
longed for approximately 2 weeks, strong inhibition of
RET phosphorylation and cell proliferation was detected
at a ponatinib concentration of 1 nM. Plasma levels ex-
ceeding the in vitro IC50 values for RET were previously
reported to be sustained inmice for at least6 hours with
30mg/kg oral dosing, declining to 8 nM at 24 hours post-
dose (18). Here we show that 30 mg/kg (P  .001) or 20
mg/kg (P .05) ponatinibdoses reducedgrowthofTTcell
xenografts in nude mice as well as RET phosphorylation.
In TT cell xenografts, RET target inhibition was observed
as early as 5 hours after 30 mg/kg ponatinib dosing. A
limitation of our study is that a dose-response experiment
was not performed to determine the minimal ponatinib
dose effective in the mouse TT cell xenograft. However, it
is important to note that at doses of 30 mg, the trough
bloodponatinib concentration surpassed40nMinhuman
patients with leukemia (34).
Ponatinib is a multitargeted agent and its effects in
MTC cells can result from the inhibition of other targets
besides RET. At variance from other known ponatinib
targets, VEGFR-2/KDR is expressed and phosphorylated
in both MTC samples (35) and cell lines (15), and
ponatinib efficiently blocked VEGFR-2/KDR phosphor-
ylation in MTC cells. Thus, it is possible that VEGFR-2/
KDR inhibition may cooperate with RET inhibition in
mediating ponatinib effects in MTC cells.
RET mutants in the gatekeeper (V804) or the adjacent
Y806 residue are resistant to both vandetanib and pyra-
zolopirimidines (PP1 and PP2) (24, 30). Ponatinib inhib-
ited V804M/L and Y806C RET protein mutants, al-
though at doses higher than those required to inhibit the
other RET mutants. This result is consistent with the no-
tion that ponatinib inhibits efficiently the T315I gate-
keepermutant ofBCR-ABL (18), as well asmultiresistant
FLT3-ITD F691I mutant (36). Mutations targeting the
RET residue Y806 are exceedingly rare; V804, instead, is
quite commonly mutated in both familial (from 5% to
32%) and sporadic cases of MTC, particularly in some
geographic regions (37).
MTC is commonly associated with RET oncogenic
conversion and 2 multitarget agents with RET inhibitory
activity, vandetanib and cabozantinib, have been recently
approved for MTC treatment (16, 17). Given the potent
anti-RET activity of ponatinib, our data suggest that it
may be worth testing in patients affected by MTC and
possibly other RET-driven neoplasms.
Acknowledgments
We thank R. F. Gagel (Department of Endocrine Neoplasia and
Hormonal Disorders, The University of Texas MD Anderson
CancerCenter,Houston, Texas) forMZ-CRC-1,N. Fabien (De-
partment of Immunology, Centre Hospitalier Lyon-Sud, Hos-
pices Civils de Lyon, Inserm U851, Pierre-Benite) for BCPAP,
and M. Nagao (Carcinogenesis Division, National Cancer Cen-
ter Research Institute, Tokyo, Japan) for TPC1 cells. We thank
Salvatore Sequino (Dipartimento diMedicinaMolecolare e Bio-
tecnologie Mediche, Università di Napoli, Federico II, Naples,
Italy) for animal care.
Address all correspondence and requests for reprints to:Mas-
simo Santoro, MD, PhD, Dipartimento di Biologia e Patologia
Cellulare e Molecolare, Università di Napoli Federico II, via S.
Pansini 5, 80131 Naples, Italy. E-mail: masantor@unina.it.
This work was supported by the Associazione Italiana per la
Ricerca sul Cancro (Grant IG11822) and the Italian Ministero
dell’Università e della Ricerca (Grants MERIT-RBNE08YFN3
and 2009X23L78_002) from ItalianMinistero dell’Università e
della Ricerca.
Disclosure Summary: J.M.G. is a full-time employee of
ARIADPharmaceuticals, Inc, and has equity interests in ARIAD
Pharmaceuticals, Inc. The other authors have nothing to
disclose.
References
1. Wells SA Jr, Santoro M. Targeting the RET pathway in thyroid
cancer. Clin Cancer Res. 2009;15:7119–7123.
2. Eng C. Common alleles of predisposition in endocrine neoplasia.
Curr Opin Genet Dev. 2010;20:251–256.
3. de Groot JW, Links TP, Plukker JT, Lips CJ, Hofstra RM. RET as
a diagnostic and therapeutic target in sporadic and hereditary en-
docrine tumors. Endocr Rev. 2006;27:535–560.
4. NikiforovYE,NikiforovaMN.Molecular genetics and diagnosis of
thyroid cancer. Nat Rev Endocrinol. 2011;7:569–580.
5. LipsonD,CapellettiM,YelenskyR, et al. Identification of newALK
and RET gene fusions from colorectal and lung cancer biopsies.Nat
Med. 2012;18:382–384.
6. Takeuchi K, SodaM,Togashi Y, et al.RET, ROS1 andALK fusions
in lung cancer. Nat Med. 2012;18:378–381.
7. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung
adenocarcinoma. Nat Med. 2012;18:375–377.
E818 De Falco et al Ponatinib-Mediated RET Inhibition J Clin Endocrinol Metab, May 2013, 98(5):E811–E819
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 24 February 2015. at 07:05 For personal use only. No other uses without permission. . All rights reserved.
8. Ballerini P, Struski S, Cresson C, et al. RET fusion genes are asso-
ciated with chronic myelomonocytic leukemia and enhance mono-
cytic differentiation. Leukemia. 2012;26:2384–2389.
9. Beaudry P, Nilsson M, Rioth M, et al. Potent antitumor effects of
ZD6474 on neuroblastoma via dual targeting of tumor cells and
tumor endothelium. Mol Cancer Ther. 2008;7:418–424.
10. Gil Z, Cavel O, Kelly K, et al. Paracrine regulation of pancreatic
cancer cell invasion by peripheral nerves. J Natl Cancer Inst. 2010;
102:107–118.
11. Morandi A, Plaza-Menacho I, Isacke CM. RET in breast cancer:
functional and therapeutic implications. Trends Mol Med. 2011;
17:149–157.
12. Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M.
New therapeutic approaches to treat medullary thyroid carcinoma.
Nat Clin Pract Endocrinol Metab. 2008;4:22–32.
13. Sherman SI. Targeted therapies for thyroid tumors. Mod Pathol.
2011;24(Suppl 2):S44–S52.
14. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally
available inhibitorofKDRtyrosinekinase activity, efficientlyblocks
oncogenic RET kinases. Cancer Res. 2002;62:7284–7290.
15. Vitagliano D, De Falco V, Tamburrino A, et al. The tyrosine kinase
inhibitor ZD6474 blocks proliferation of RET mutant medullary
thyroid carcinoma cells. Endocr Relat Cancer. 2010;18:1–11.
16. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients
with locally advanced or metastatic medullary thyroid cancer: a
randomized, double-blind phase III trial. J Clin Oncol. 2012;30:
134–141.
17. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabo-
zantinib), an oral tyrosine kinase inhibitor, in patients with medul-
lary thyroid cancer. J Clin Oncol. 2011;29:2660–2666.
18. O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-
ABL inhibitor for chronic myeloid leukemia, potently inhibits the
T315I mutant and overcomes mutation-based resistance. Cancer
Cell. 2009;16:401–412.
19. Gozgit JM,WongMJ,Wardwell S, et al.Potent activity of ponatinib
(AP24534) in models of FLT3-driven acute myeloid leukemia and
other hematologic malignancies.Mol Cancer Ther. 2011;10:1028–
1035.
20. Gozgit JM,WongMJ,Moran L, et al. Ponatinib (AP24534), a mul-
titargeted pan-FGFR inhibitor with activity in multiple FGFR-am-
plified or mutated cancer models.Mol Cancer Ther. 2012;11:690–
699.
21. Zhou T, Commodore L, HuangWS, et al. Structural mechanism of
the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for over-
coming kinase inhibitor resistance. Chem Biol Drug Des. 2011;77:
1–11.
22. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory
Philadelphia chromosome-positive leukemias.NEngl J Med. 2012;
367:2075–2088.
23. Pasini A, Geneste O, Legrand P, et al.Oncogenic activation of RET
by two distinct FMTC mutations affecting the tyrosine kinase do-
main. Oncogene. 1997;15:393–402.
24. Carlomagno F, Guida T, Anaganti S, et al. Disease associated mu-
tations at valine 804 in the RET receptor tyrosine kinase confer
resistance to selective kinase inhibitors.Oncogene. 2004;23:6056–
6063.
25. Berger CL, de Bustros A, Roos BA, et al.Humanmedullary thyroid
carcinoma in culture provides a model relating growth dynamics,
endocrine cell differentiation, and tumor progression. J Clin Endo-
crinol Metab. 1984;59:338–343.
26. Carlomagno F, Salvatore D, SantoroM, et al. Point mutation of the
RETproto-oncogene in theTThumanmedullary thyroid carcinoma
cell line. Biochem Biophys Res Commun. 1995;207:1022–1028.
27. Huang SC, Torres-Cruz J, Pack SD, et al. Amplification and over-
expressionofmutantRET inmultiple endocrineneoplasia type2-as-
sociated medullary thyroid carcinoma. J Clin Endocrinol Metab.
2003;88:459–463.
28. Cooley LD, Elder FF, Knuth A, Gagel RF. Cytogenetic character-
ization of three human and three rat medullary thyroid carcinoma
cell lines. Cancer Genet Cytogenet. 1995;80:138–149.
29. Salerno P, De Falco V, Tamburrino A, et al. Cytostatic activity of
adenosine triphosphate-competitive kinase inhibitors in BRAF mu-
tant thyroid carcinoma cells. J Clin Endocrinol Metab. 2010;95:
450–455.
30. Carlomagno F, Guida T, Anaganti S, et al. Identification of tyrosine
806 as a molecular determinant of RET kinase sensitivity to
ZD6474. Endocr Relat Cancer. 2009;16:233–241.
31. Carlomagno F, Anaganti S, Guida T, et al. BAY 43–9006 inhibition
of oncogenic RET mutants. J Natl Cancer Inst. 2006;98:326–334.
32. BorrelloMG, PelicciG,Arighi E, et al.Theoncogenic versions of the
Ret and Trk tyrosine kinases bind Shc and Grb2 adaptor proteins.
Oncogene. 1994;9:1661–1668.
33. Asai N, Murakami H, Iwashita T, Takahashi M. A mutation at
tyrosine 1062 inMEN2A-Ret andMEN2B-Ret impairs their trans-
forming activity and association with shc adaptor proteins. J Biol
Chem. 1996;271:17644–17649.
34. Cortes J, TalpazM, Bixby D, et al.A phase 1 trial of oral ponatinib
(AP24534) in patients with refractory chronic myelogenous leuke-
mia (CML) and other hematologic malignancies: emerging safety
and clinical response findings. Blood 2010;116:210.
35. Rodríguez-Antona C, Pallares J, Montero-Conde C, et al. Overex-
pression and activation of EGFR andVEGFR2 inmedullary thyroid
carcinomas is related to metastasis. Endocr Relat Cancer. 2010;17:
7–16.
36. Zirm E, Spies-Weisshart B, Heidel F, et al. Ponatinib may overcome
resistance of FLT3-ITD harbouring additional point mutations, no-
tably the previously refractory F691I mutation. Br J Haematol.
2012;157:483–492.
37. Romei C, Mariotti S, Fugazzola L, et al. Multiple endocrine neo-
plasia type 2 syndromes (MEN2): results from the ItaMENnetwork
analysis on the prevalence of different genotypes and phenotypes.
Eur J Endocrinol. 2010;163:301–308.
doi: 10.1210/jc.2012-2672 jcem.endojournals.org E819
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 24 February 2015. at 07:05 For personal use only. No other uses without permission. . All rights reserved.
JCEM JC-12-2672v4 
Ponatinib-mediated RET inhibition 
Supplemental informations 
 1
 
Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated to thyroid 
cancer 
Valentina De Falco, et al. 
 
Supplemental informations 
Inventory: 
-Supplemental Methods 
-Supplemental Results 
-Supplemental Figures and Legends 
-Supplemental Table 
 
 
Supplemental Methods 
Compounds   For in vitro experiments, ponatinib was dissolved in dimethyl sulfoxide (DMSO) at a 
concentration of 10 mM and stored at –80°C. For in vivo experiments, it was dissolved in sodium 
citrate, pH 2.7, and stored at room temperature.  
 
Cell Cultures   HEK293 cells were from American Type Culture Collection (ATCC, Rockville, 
MD) and were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal 
calf serum (Invitrogen, Carlsbad, CA, USA). Transient transfections were carried out with the 
FuGENE HD reagent according to manufacturer's instructions (Roche, Mannheim, Germany). 
NIH3T3 and RAT1 fibroblasts were grown in DMEM supplemented with 5% calf serum. TT cell line 
was obtained in 2002 from ATCC and authenticated by RET genotyping. TT cells were grown in 
RPMI 1640 supplemented with 16% fetal calf serum (Invitrogen). MZ-CRC-1 cells were kindly 
provided in 2009 by Robert F. Gagel (MD Anderson, Houston, TX) and authenticated by RET 
genotyping. MZ-CRC-1 cells were grown in DMEM supplemented with 10% fetal calf serum 
(Invitrogen). Human papillary thyroid cancer BCPAP cells were obtained in 1994 from N. Fabien 
(CNRS, Oullins, France) and TPC-1 cells were obtained in 1990 from M. Nagao (National Cancer 
Center Research Institute, Tokyo, Japan). These cell lines were grown in DMEM with 10% fetal calf 
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serum (Invitrogen). Nthy-ori 3-1 cells were obtained from European Collection of Cell Cultures 
(ECACC) (Wiltshire, UK) in 2010 and were grown in RPMI supplemented with 10% fetal calf serum 
(Invitrogen).  All media were supplemented with 2 mM L-glutamine and 100 units/ml penicillin-
streptomycin (Invitrogen). All cells were passaged for fewer than 2 months after resuscitation. 
 For cell proliferation assays, 1x104 (NIH3T3, NIH RET/C634Y, NIH RET/M918T), 5x103 
(NIH HRAS/G12V), 3x104 (Nthy-ori 3-1, BCPAP), 7x104 (TPC-1), 3x105 (TT), or 1x105 (MZ-CRC-
1) cells were plated in 35-mm dishes. The day after plating, the cells were counted and the compound 
or vehicle were added. Cells were counted in triplicate at the indicated time points and the number of 
cells at the last day of the experiment was used to calculate growth inhibition. 
 
Plasmids  Plasmids encoding wild type RET, oncogenic RET point mutants (C634R, E768D, 
L790F, Y791F, V804M, Y806C, A883F, E884K, S891A, D898V, M918T) and RET rearrangements 
(RET/PTC1, RET/PTC3) were cloned in the pBABE expression vector.  
 
Protein Studies   Immunoblotting experiments were performed according to standard procedures. 
Briefly, cells were harvested in lysis buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 10% glycerol, 1% 
Triton X-100, 1 mM EGTA, 1.5 mM MgCl2, 10 mM NaF, 10 mM sodium pyrophosphate, 1 mM 
Na3VO4, 10 µg of aprotinin/ml, 10 µg of leupeptin/ml) and clarified by centrifugation at 10,000 x g. 
Protein concentration was estimated with a modified Bradford assay (Bio-Rad Laboratories, Berkeley, 
CA, USA). Antigens were revealed by an enhanced chemiluminescence detection kit (ECL, 
Amersham Pharmacia Biotech). Signal intensity was quantified with the Phosphorimager (Typhoon 
8600, Amersham Pharmacia Biotech) interfaced with the ImageQuant software. Anti-phospho-SHC, 
which recognizes SHC proteins when phosphorylated at Y317 (#07-206), was from Upstate 
Biotechnology Inc. (Lake Placid, NY, USA). Anti-phospho-PLCY783 -VEGFR-2/KDR 
(Y1175) (#2478), -MAPK (ERK) (T302/Y304) (#9102), -AKT (S473) (#9271), -S6 (S240/S244) 
(#2215), -ABL (#2861), and -SRC  (#2101) were from Cell Signaling Technologies (Danvers, MA, 
USA). Anti-phospho-EGFR (#44788G) was from Invitrogen (Carlsbad, CA, USA). Monoclonal anti-
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α-tubulin was from Sigma Aldrich (St Louis, MO, USA). Anti-RET is a polyclonal antibody raised 
against the tyrosine kinase protein fragment of human RET. Anti-pY905 and anti-pY1062 are 
phospho-specific affinity-purified polyclonal antibodies that recognize RET proteins phosphorylated 
at Y905 and Y1062, respectively. Monoclonal anti-α-tubulin was from Sigma Aldrich (St Louis, MO, 
USA). Secondary antibodies coupled to horseradish peroxidase were from Amersham Pharmacia 
Biotech.  
 
In vitro kinase assay   Subconfluent cells were solubilized in lysis buffer without phosphatase 
inhibitors. Then, 50 g of proteins were immunoprecipitated with anti-RET; immunocomplexes were 
recovered with protein A sepharose beads, washed 5 times with kinase buffer, and incubated 20 min at 
room temperature in kinase buffer containing 2.5 Ci -32P ATP and unlabelled ATP to a final 
concentration of 20 M. Samples were separated by SDS-PAGE. Gels were dried and exposed to 
autoradiography. Signal intensity was analyzed by the Phosphorimager (Typhoon 8600) interfaced 
with the ImageQuant software. Half maximal kinase inhibitory concentration (IC50) value was 
calculated by using PRISM (GraphPad software). 
 
Phospho-RTK Array   The relative levels of tyrosine phosphorylation of 42 receptor tyrosine 
kinases (RTKs) were evaluated with a Human Phospho-RTK array (R&D Systems, Inc. Minneapolis, 
MN, USA). Each array contained 42 different anti-RTK antibodies and six controls printed in 
duplicate. Briefly, cells were lysed in NP-40 lysis buffer (1% NP-40, 20 mM Tris-HCl pH 8.0, 137 
mM NaCl, 10% Glycerol, 2 mM EDTA, 1 mM Sodium Orthovanadate, 10 g/ml Aprotinin, 10 g/ml 
Leupeptin) and centrifuged at 14,000 g for 30 minutes at 4°C. Non-specific binding was blocked for 1 
hour at room temperature on a rocking platform. For each filter, 500 g of protein lysate was used. 
The lysates were diluted in Array Buffer 1 (provided with the kit), added to each array, and incubated 
overnight at 4°C. Freshly diluted detection antibody was added to the arrays for 2 hours of room 
temperature. Phosphorylation levels were detected by chemiluminescence (ECL; Amersham 
Pharmacia Biotech). 
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Histological examination and immunohistochemistry  Tumor samples were fixed in 10% neutral-
buffered formalin, embedded in paraffin, and 5 μm sections were stained with haematoxylin-eosin 
according to standard procedures. Extent of tumor necrosis or fibrosis was assessed as percentage of 
the total tumor area. Mitotic Index (MI) was assessed by counting mitotic figures in the cell dense 
areas at the periphery of the sample in 5 high-power (40 × objective, area of single field 0.166 mm2) 
fields. Ki-67 expression was detected by incubating the slides with the rabbit monoclonal primary 
antibody (clone 30-9) (Ventana Medical System, ready to use for the Ventana automated slide stainer). 
Ki-67 staining was expressed as the percentage of cancer cells with positively-stained nuclei, counting 
at least 1,000 cells at 40 × magnification. Caspase 3 cleavage was assessed by immunostain with anti-
cleaved caspase-3 (Asp175) antibody (Cell Signaling, #9664) and expressed as the number of cleaved 
caspase-3 immunoreactive cells out of 2,000 neoplastic cells at in fields distant from necrotic areas 
(40 × magnification). Immunoreactions were displayed by the avidin–biotin–peroxidase complex 
(ABC) method by a Benchmark immunostainer (Ventana, Tucson, AZ). Counterstaining was 
performed with haematoxylin. Negative controls were carried out by omitting the primary antibodies. 
Immunohistochemical evaluation was determined by 2 pathologists (LT and FB) blinded to the 
treatment code. Microvascular count (MVC) was determined using anti-FVIII polyclonal antibody 
(Ventana Medical System, ready to use for the Ventana automated slide stainer). A single microvessel 
was defined as any brown immunostained endothelial cell separated from adjacent microvessel, tumor 
cells and other connective tissue elements. Areas with most intense vascularization (hot spot) under 
low microscopic power were scanned at 20 × magnification and the number of stained blood vessels 
was counted in 5 fields. Large vessels with thick, muscular walls were excluded from the counts. The 
sections were observed under a light microscope and photographed by digital camera (Olympus, 
Tokyo, Japan).  
 
Statistical Analysis  Kinase activity curves were graphed using the curve-fitting PRISM (GraphPad 
software). To compare cell growth, we used the One-way ANOVA with standard parametric methods 
JCEM JC-12-2672v4 
Ponatinib-mediated RET inhibition 
Supplemental informations 
 5
and the Bonferroni Multiple Comparison Test (InStat program, GraphPad software). To compare 
tumor growth, we used the One-way ANOVA with standard parametric methods and the Tukey-
Kramer Multiple Comparison Test (InStat program, GraphPad software). P values were statistically 
significant at P <.05.  
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Supplemental Results 
 
Growth curves  
NIH3T3-derived cell lines were incubated with vehicle or the indicated ponatinib doses in 5% and 
2.5% calf serum (parental and transfected cells, respectively), and counted at 6 days. % change with 
respect to initial cell number is reported in Figure 2. In details: RET/C634Y cells treated (6 days) with 
vehicle numbered 2,155 x 103 (95% CI=1,771 x 103 to 2,539 x 103) and those treated with 5 nM 
ponatinib numbered 1,435 x 103 (95% CI=1,162 x 103 to 1,708 x 103) (P < .001); RET/M918T cells 
treated (6 days) with vehicle numbered 3,357 x 103 (95% CI=3,261 x 103 to 3,453 x 103) while those 
treated with 5 nM ponatinib numbered 2,170 x 103 (95% CI=1,944 x 103 to 2,396 x 103), respectively 
(P <.001); NIH cells treated (6 days) with vehicle numbered 2,201 x 103 (95% CI=1,649 x 103 to 
2,753 x 103) while those treated with 5 nM ponatinib numbered 1,953 x 103 (95% CI=1,397 x 103 to 
2,508 x 103) (P >.05); HRAS/G12V cells treated (6 days) with vehicle numbered 917.0 x 103 (95% 
CI=786.6 x 103 to 1,047 x 103) while those treated with 5 nM of ponatinib numbered 855.8 x 103 (95% 
CI=741.2 x 103 to 970.4 x 103) (P >.05). 
 Human thyroid cell lines were incubated with vehicle or different doses of ponatinib in 2.5% 
(BCPAP, Nthy-ory 3-1, TPC-1, MZ-CRC-1) or 4% (TT) serum and counted at 4 days. % change with 
respect to initial cell number is reported in Figure 3. In details: Nthy-ory 3-1 cells treated with vehicle 
numbered 389.9 x 103 (95% CI=254.8 x 103 to 525.0 x 103), those treated with 5 nM ponatinib 
numbered 345.6 x 103 (95% CI=237.1 x 103 to 454.0 x 103) (P >.05), and those treated with 50 nM 
ponatinib numbered 262.0 x 103 (95% CI=245.9 x 103 to 278.2 x 103) (P <.01); BCPAP cells treated 
with vehicle numbered 398.2 x 103 (95% CI=331.1 x 103 to 465.2 x 103), those treated with 5 nM 
ponatinib numbered 443.5 x 103 (95% CI=386.8 x 103 to 500.2 x 103) (P >.05) and those treated with 
50 nM ponatinib numbered 370.5 x 103 (95% CI=354.6 x 103 to 386.4 x 103) (P >.05); TPC-1 cells 
treated with vehicle numbered 212.3 x 104 (95% CI=148.0 x 104 to 276.6 x 104) while those treated 
with 5 nM ponatinib numbered 121.1 x 104 (95% CI=110.5 x 104 to 131.6 x 104) (P <.001); TT cells 
treated with vehicle numbered 109.3 x 103 (95% CI=80.2 x 103 to 138.5 x 103) while those treated 
with 5 nM ponatinib numbered 62.5 x 103 (95% CI=33.1 x 103 to 91.9 x 103) (P <.05); MZ-CRC-1 
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cells treated with vehicle numbered 73.6 x 103 (95% CI=49.3 x 103 to 97.9 x 103) while those treated 
with 5 nM of ponatinib numbered 50.1 x 103 (95% CI=40.1 x 103 to 60.1 x 103) (P <.05) 
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Supplemental Figures and Legends 
 
Fig. 1 
 
 
Fig. 1. In vitro inhibition of RET mutants by ponatinib. Upper) Schematic representation of RET 
mutants used in this study: SP: signal peptide; EC: extracellular domain; Cys: cysteine rich domain; 
TM: transmembrane domain; JX: juxtamembrane domain TK: tyrosine kinase domain; X: RET fusion 
partners. Bottom) Inhibition of oncogenic RET mutants phosphorylation and signaling by ponatinib. 
Serum-starved (18 hours) cells, transfected with the indicated RET constructs, were treated with 
different concentrations of drug for 1 hour; 50 g of total cell lysates were subjected to 
immunoblotting with antibodies specific for phospho-RET/Y905 or -RET/Y1062. SHC protein 
phosphorylation was measured by a phospho-specific antibody. Equal gel loading was determined by 
anti-RET antibody. Data are representative of 3 independent experiments. 
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Fig. 2 
 
 
 
Fig. 2. In vitro RET auto-phosphorylation assay. Protein extracts from RAT1-RET/V804M cells were 
immunoprecipitated with anti-RET and subjected to an immunocomplex kinase assay in the presence 
of -32P ATP. Ponatinib or vehicle alone (DMSO) were added to the reaction mixture to reach the 
indicated concentrations. Reaction products were separated by SDS-PAGE and autoradiographed. 
Phosphor-imaging was used to quantify the results. Each point represents the mean value for 4 
independent determinations and is plotted as percentage of residual activity; error bars represent 95% 
confidence intervals. IC50 value (PRISM, GraphPad Software) was indicated. 
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Fig. 3 
 
Fig. 3. RTK inhibition by ponatinib in TT and MZ-CRC-1 cells A) Protein lysates (500 g) from TT 
or MZ-CRC-1 cells were added to each array, and incubated overnight at 4°C. Detection antibody was 
added to the arrays for 2 hours of room temperature and phosphorylation levels of 42 different RTK as 
duplicated spots were detected by chemiluminescence. B) TT cells were treated with different 
concentrations of ponatinib (AP24534) for 1 hour; 50 g of total cell lysates were subjected to 
immunoblotting with antibody specific for phospho-RET/Y905, phospho-KDR/Y1175, phospho-
EGFR/Y1068, phospho-SRC/Y416, or phospho-ABL/Y245. Equal gel loading was determined by 
anti-tubulin antibody. The signal was analyzed at the Phosphorimager. Data are representative of 3 
independent experiments. 
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Fig. 4 
 
Fig. 4. Effects on mice weight by ponatinib in mice xenografted with TT cells. A) TT cells 
(5x107/mouse) were inoculated as described in Fig.4A. When tumors measured 100-150 mm3, 
animals were randomly assigned to receive ponatinib (30 mg/kg/day) (n. 10) or vehicle (n. 9) by oral 
gavage. Treatment was administered for 5 consecutive days/week for three weeks (day 0 is the 
treatment starting day). Mice weights were measured. Error bars represent 95% confidence intervals. 
P value for the comparisons at 21 days between compound and vehicle is indicated. Statistical 
significance was determined by the one-way ANOVA with the Tukey-Kramer Multiple Comparison 
Test. B) TT cells (5x107/mouse) were inoculated as described in Fig.4B. When tumors measured 
650-700 mm3, animals were randomly assigned to receive ponatinib (30 mg/kg/day) (n. 6) or vehicle 
(n. 6) by oral gavage. Treatment was administered for 3 consecutive days, interrupted for 2 days and 
administered again for 2 consecutive days (day 0 is the treatment starting day). Mice weights were 
measured. Error bars represent 95% confidence intervals. P value for the comparisons at 7 days 
between compound and vehicle is indicated. Statistical significance was determined by the one-way 
ANOVA with the Tukey-Kramer Multiple Comparison Test.  
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Fig. 5 
 
 
 
Fig. 5 In vivo inhibition of RET by ponatinib in mice xenografted with TT cells. TT cells 
(5x107/mouse) were inoculated subcutaneously into the right dorsal portion of BALB/c nude mice. 
When tumors measured 500 mm3, animals were randomly assigned to receive per os a single dose of 
ponatinib (30 mg/kg) (T1, T2, T3, T4) or vehicle (NT1, NT2) for 5 hours. 50 g of total cell lysates 
were subjected to immunoblotting with antibody specific for phospho-RET/Y905 or -RET/Y1062. 
Equal gel loading was determined by anti-RET antibody. The signal was analyzed at the 
Phosphorimager.  
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Fig. 6 
 
Fig. 6 Anti-tumorigenic effects of ponatinib (20 mg/kg/day) in TT cells xenografts. A) TT cells 
(5x107/mouse) were inoculated as described in Fig. 4. When tumors measured 400 mm3, animals 
were randomly assigned to receive ponatinib (20 mg/kg/day) (n. 8) or vehicle (n. 7) by oral gavage. 
Treatment was administered for 3 consecutive days, interrupted for 2 days and administered again for 
2 consecutive days (day 0 is the treatment starting day). Tumor diameters were measured with calipers 
and tumor volumes were calculated. Error bars represent 95% confidence intervals. P values for the 
comparisons between compound and vehicle are reported. Statistical significance was determined by 
the one-way ANOVA with the Tukey-Kramer Multiple Comparison Test. B) Protein lysates (50 g) 
were subjected to immunoblotting with antibody specific for RET or phospho-RET/Y1062. The signal 
was analyzed at the Phosphorimager and expressed as pRET/RET fraction.
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Table 1. Histopathologic examination of ponatinib effects in TT cell xenografts  
ID Ki-67 (%)1 
 
Mitotic index2  
(n° mitosis per 5 HPF)  
T vs NT P<.001 
Apoptotic index3 
(n° of cleaved 
caspase-3 positive 
apoptotic cells )  
T vs NT P<.001 
Necrosis (%)4  
T vs NT P>.05 
Fibrosis (%)5  
T vs NT P<.001 
1 NT TMTM 26 15 10 0 
2 NT TMTM 25 16 5 0 
3 NT TMTM 28 16 5 0 
4 NT TMTM 24 17 5 0 
5 NT TMTM 22 17 5 0 
6 NT TMTM 23 22 2 0 
7 NT TMTM 28 18 5 0 
8 NT TMTM 25 16 10 0 
1 T 5 1 56 20 5 
2 T 5 1 37 5 30 
3 T 5 0 50 10 20 
4 T 5 0 34 5 30 
5 T 2 1 38 5 30 
6 T 5 1 34 10 30 
7 T 5 0 27 5 5 
 
1Ki-67 immunostaining was expressed as the percentage of cancer cells with positively-stained nuclei, 
counting at least 1,000 cells at 40 × magnification. TMTM: too many to count 
2 Mitotic Index (MI) was assessed by counting mitotic figures in the cell dense areas at the periphery 
of the sample in 5 high-power (40 × objective, area of single field 0.166 mm2) fields.  
3 The apoptotic index was calculated as the number of cleaved caspase-3 immunoreactive cells 
counting 2,000 neoplastic cells at 40 × magnification, in fields distant from necrotic areas.  
4, 5 Extent of tumor necrosis or fibrosis was assessed as percentage of the total tumor area. 
2-5P values for the comparisons between compound (NT) and vehicle (T) are indicated. Statistical 
significance was determined by the Mann-Whitney Test. 
 
